Microorganism expressing active D-proline reductase and method for producing active D-proline reductase

Through the method of co-expressing PrdH protein and PrdA and PrdB proteins, the technical problem of D-proline reductase activation was solved, the activity enhancement of D-proline reductase and the effective production of its analogs was achieved, and the nylon was expanded Possibility of synthesis.

CN111032874BActive Publication Date: 2024-11-08CJ CHEILJEDANG CORP
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN201880046286.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-07-12
Filing Date
2018-07-12
Publication Date
2024-11-08
Estimated Expiration
2039-04-11

AI Technical Summary

Technical Problem

The prior art is difficult to effectively activate D-proline reductase, which limits its application in nylon synthesis, especially due to the self-cleaving instability of PrdA protein and the difficulty in introducing pyruvate acyl, resulting in active D-proline reductase. The preparation and application are limited.

Method used

By expressing the PrdH protein co-expressing with PrdA and PrdB proteins, the pyruvate group is accurately self-cleaved and introduced, thereby converting the inactive D-proline reductase into the active form, and a new active D-proline reductase system is constructed.

Benefits of technology

Successfully increased the activity of D-proline reductase, providing new methods for the production of active D-proline and its analogues such as 5-aminovaleric acid and γ-aminobutyric acid, which enhances its in nylon Application potential in synthesis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111032874B_ABST
    Figure CN111032874B_ABST
Patent Text Reader

Abstract

The present disclosure relates to microorganisms expressing active D-proline reductase.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to a microorganism expressing D-proline reductase, wherein the activities of PrdA protein, PrdB protein and PrdH protein are enhanced; and a method for producing the corresponding active D-proline reductase. On this basis, the present disclosure also relates to a method for reducing D-proline and D-proline analogs; and a PrdH protein having the activity of converting an inactive D-proline reductase into an active D-proline reductase when co-expressed with a PrdA protein and a PrdB protein. Background Art

[0002] Due to the trend of environmentally friendly products and the unstable oil supply and oil consumption crisis, research and development of biomass-derived products such as bioplastics, bioenergy, etc. have been conducted. In particular, many studies are being conducted to apply various biomass-derived monomers to nylon. For example, research is being conducted to develop nylon 4,6 by applying biomass-derived putrescine, and to develop nylon 5,6 by applying biomass-derived cadaverine to replace hexamethylenediamine (HMDA) of nylon 6,6. The development of nylon 4 products by using 4-aminobutyric acid (or γ-aminobutyric acid (GABA)) as a monomer, which can be produced from glutamic acid as a raw material by glutamate decarboxylase, is also underway.

[0003] It is known that 5-aminovaleric acid, which is a monomer of nylon 5, is converted from proline by D-proline reductase. However, the activation of D-proline reductase requires precise self-cleavage of the PrdA protein and simultaneous introduction of a pyruvyl group. However, this is considered to be a technical limitation, and thus there is an increasing demand for methods capable of preparing active D-proline reductase. Summary of the invention

[0004] Technical issues

[0005] The present inventors continued to study recombinant expression systems and microbial strains that can produce active forms of D-proline reductase, and also studied their applicability to various D-proline analog substrates. As a result, they identified for the first time a PrdH protein that converts inactive D-proline reductase into active D-proline reductase when co-expressed with a PrdA protein and a PrdB protein. Further, they successfully demonstrated the activity of a microorganism expressing active D-proline reductase and the D-proline reductase produced therefrom.

[0006] Technical Solution

[0007] An object of the present disclosure is to provide a microorganism expressing active D-proline reductase, wherein the activities of PrdA protein, PrdB protein, and PrdH protein are enhanced.

[0008] Another object of the present disclosure is to provide a method for producing active D-proline reductase, which comprises the steps of culturing a microorganism in a culture medium, and recovering the active D-proline reductase from the microorganism or the culture medium.

[0009] Still another object of the present disclosure is to provide a method for producing one or more selected from aminovaleric acid (5-aminovaleric acid, 5-AVA), γ-aminobutyric acid (GABA) and 5-amino-4-hydroxyvaleric acid using an active D-proline reductase produced by a microorganism or a microorganism.

[0010] Still another object of the present disclosure is to provide a PrdH protein that converts inactive D-proline reductase into active D-proline reductase when co-expressed with a PrdA protein and a PrdB protein.

[0011] Still another object of the present disclosure is to provide a method for producing a microorganism expressing active D-proline reductase, the method comprising the steps of transforming a host cell with an expression cassette comprising a prdA gene or prdA and prdH genes, and transforming a host cell with an expression cassette comprising a prdB gene or prdB and prdH genes.

[0012] Beneficial Effects

[0013] In the present disclosure, a polypeptide capable of converting an inactive D-proline reductase into an active D-proline reductase is newly proposed, and when expressed by interacting with a complex of PrdA and PrdB constituting an existing D-proline reductase or when expressed together with a Prd operon, the activity of the active D-proline reductase is enhanced, thereby providing a novel active form of D-proline reductase and a method for converting D-proline or an analog thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 is a schematic diagram showing a method for producing active D-proline reductase.

[0015] Figure 2 The results of SDS-PAGE analysis according to the expression conditions of the PrdA protein are shown.

[0016] Figure 3 Shown are the results of SDS-PAGE analysis of PrdA protein expression with or without shaking.

[0017] Figure 4 The results of Western blot analysis according to PrdB protein expression are shown.

[0018] Figure 5 The results of Western blot analysis of self-cleavage of PrdA protein by PrdH protein are shown.

[0019] Figure 6 The results of TLC analysis of the activities of recombinant D-proline reductase and PrdDEE2 proteins are shown.

[0020] Figure 7 The results of Western blot analysis using the universal PrdH protein are shown.

[0021] Figure 8 The results of TLC analysis showing the effect of the PrdC protein on the activity of D-proline reductase.

[0022] Fig. 9 Results of TLC analysis showing the effect of PrdG protein on the activity of D-proline reductase (A) and the properties of PrdG protein (B);

[0023] Fig.10 shows the results of TLC analysis of the production of 5-aminovaleric acid from a sugar source by co-expressing recombinant active D-proline reductase and an additional protein; and

[0024] Fig.11 The results of TLC analysis of the D-proline analog conversion ability of the active D-proline reductase are shown. DETAILED DESCRIPTION

[0025] The present disclosure will be described in detail below. At the same time, each description and embodiment disclosed in the present disclosure can also be applied to other descriptions and embodiments. That is to say, all combinations of various elements disclosed in the present disclosure fall within the scope of the present disclosure. Further, the scope of the present disclosure is not limited by the specific embodiments described below.

[0026] To achieve the purpose of the present disclosure, one aspect of the present disclosure provides a microorganism expressing active D-proline reductase, wherein the activities of the PrdA protein, the PrdB protein, and the PrdH protein are enhanced.

[0027] As used herein, the term "D-proline reductase" refers to a protein complex composed of PrdA protein and PrdB protein. Its main function is known to participate in the conversion process of reducing D-proline to 5-aminovaleric acid (5-AVA). It is known that this reaction corresponds to the last step of the Stickland reaction, which is used for energy (ATP) supply of anaerobic strains (Bouillaut et al., J. Bacteriol., 2013, 195 (4), 844-854).

[0028] The Stickland reaction, also known as the Stickland fermentation, refers to a reaction involving the oxidation and reduction of an amino acid to an organic acid. In detail, the electron donor amino acid is oxidized to a volatile carboxylic acid that is one carbon atom shorter than the original amino acid. For example, alanine, which has a three-carbon chain, is converted to acetic acid, which has two carbons. Amino acids can act as both Stickland acceptors and Stickland donors.

[0029] Representative strains having a Stickland reaction may include Peptoclostridium difficile 630, Clostridium difficile 630, Peptoclostridium stiklandii, Clostridium stiklandii, or Eubacterium aminophilum. Some lactobacillus strains, such as Lactobacillus salivarius, are also known. Therefore, these strains can be used to produce microorganisms expressing the active D-proline reductase of the present disclosure, PrdH proteins having the activity of converting inactive D-proline reductase into active D-proline reductase, and active D-proline reductase.

[0030] The main function of known D-proline reductase is to participate in the conversion process of D-proline to 5-aminovaleric acid (5-AVA). However, to date, the reaction mechanism of D-proline reductase is unclear, but the following reaction mechanism has been proposed. First, in the constituent proteins of D-proline reductase composed of a complex of α-PrdA, β-PrdA and PrdB proteins, the α-PrdA protein has a pyruvyl group at the amino terminal, which interacts with the amine group of D-proline as a substrate, and as a result, the activation energy of the substrate is reduced. In the next step, the selenocysteine ​​located on the PrdB protein destroys the CN bond between the α carbon and the amine group of D-proline, and as a result, a conversion reaction of D-proline to 5-aminovaleric acid occurs (Kabisch et al., J.Biol.Chem., 1999, 274 (13), 8445-8454). As used herein, the term "active D-proline reductase" refers to a protein complex composed of α-PrdA, β-PrdA and PrdB proteins, wherein the PrdA protein in the PrdA protein and PrdB protein constituting the D-proline reductase is separated into α-PrdA and β-PrdA due to precise self-cleavage by the auxiliary protein PrdH disclosed herein, and the pyruvyl group is bound to the amino terminus of α-PrdA. The active D-proline reductase as described above refers to the active form of the enzyme, which is capable of reducing D-proline or a D-proline analog substrate via the pyruvyl group of α-PrdA binding to the substrate. For example, the active D-proline reductase is capable of converting the substrate D-proline into 5-aminovaleric acid (5-aminovalerate).

[0031] As used herein, the term "D-proline" is an optical isomer of L-proline, which is an α-amino acid. In particular, L-proline, which is a non-essential amino acid, can be synthesized from L-glutamic acid and converted into D-proline by racemase.

[0032] As used herein, the term "PrdA protein" refers to a component of a protein complex that constitutes D-proline reductase, and the PrdA protein is separated into an α-PrdA protein (carboxyl terminal fragment) and a β-PrdA protein (amino terminal fragment) by a self-cleavage process. A general self-cleavage process occurs by simple cleavage of a peptide bond, but the self-cleavage process of the PrdA protein is characterized in that a peptide bond cleavage process and the introduction of a pyruvyl group to the amino terminus of the α-PrdA protein occur simultaneously. When the PrdA protein exists independently, a nonspecific cleavage / degradation process is involved due to defects in the protein itself, and there is a problem that the PrdA protein cannot be completely separated into an α-PrdA protein and a β-PrdA protein.

[0033] Pyruvyl is known to be an essential residue for D-proline reductase activity because it plays an important role in reducing the activation energy of the substrate (Kabisch et al., J. Biol. Chem., 1999, 274 (13), 8445-8454). However, in the protein cleavage mechanism by general hydrolysis reaction, pyruvyl is not introduced, and thus various studies have been conducted to solve this problem. In order to prevent nonspecific protein degradation caused by the structural instability of the PrdA protein (pro-PrdA protein) itself, studies have been conducted to induce an artificial cleavage process by adding a reducing agent such as NaBH4 to the PrdA protein fragment from which the amino terminus is removed. As a result, the desired site-specific cleavage was observed, but the introduction of pyruvyl was not obtained (Bednarski et al., Eur. J. Biochem., 2001, 268, 3538-3544).

[0034] The sequence of the PrdA protein can be obtained from GenBank of NCBI, which is a public database, and any sequence can be used without limitation as long as it encodes the PrdA protein of a strain having a Stickland reaction. Representative examples thereof may include PrdA proteins derived from Peptostreptococcus 630 (Clostridium difficile 630) or Lactobacillus salivarius, but are not limited thereto. For example, it may be the amino acid sequence of SEQ ID NO: 3 or the amino acid sequence encoded by the sequence of SEQ ID NO: 19, but is not limited thereto. Specifically, the PrdA protein of the present disclosure may include a polypeptide having at least 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology or identity with SEQ ID NO: 3 and SEQ ID NO: 19. Further, it is obvious that PrdA proteins having partial deletions, modifications, substitutions, conservative substitutions or additions of amino acid sequences are also within the scope of the present disclosure, as long as the amino acid sequence has the above homology or identity and exhibits the efficacy corresponding to the above proteins.

[0035] As used herein, the term "PrdB protein" refers to a component of a protein complex that constitutes D-proline reductase, and the PrdB protein is a selenoprotein that includes selenocysteine ​​(Sec), which is an unnatural amino acid. Selenocysteine ​​is known as 21 stThe non-natural amino acid of amino acid, and it is characterized in that it is not introduced into protein by normal protein synthesis mechanism (Itoh et al., Science, 340 (6128), 2013, 75-78.). In particular, since it is introduced using UGA codon, that is, the stop codon in 64 codons is carried out, there is a phenomenon that protein synthesis stops at the stop codon when there is no selenocysteine ​​insertion system. In addition, in order not to identify selenocysteine ​​insertion codon as a general stop codon, the secondary structure of the sequence / structure specific mRNA called SECIS (SElenoCysteine ​​Incorporation Sequence) must be positioned downstream of the UGA codon, and in order to be incorporated into protein, Sel system (SelABCD) is needed (Su et al., Nucleic Acids Res., 2005, 33 (8), 2486-2492).

[0036] The sequence of the PrdB protein can be obtained from GenBank of NCBI, which is a public database, and any sequence can be used without restriction as long as it encodes the PrdB protein of a strain having a Stickland reaction. Representative examples thereof may include PrdB proteins derived from Peptostreptococcus 630 (Clostridium difficile 630) or Lactobacillus salivarius, but are not limited thereto. For example, it may be the amino acid sequence of SEQ ID NO: 5 or the amino acid sequence encoded by the polypeptide sequence of SEQ ID NO: 21, but is not limited thereto. Specifically, the PrdB protein of the present disclosure may include a polypeptide having at least 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology or identity with SEQ ID NO: 5 and SEQ ID NO: 21. Further, it is obvious that PrdB proteins with partial deletions, modifications, substitutions, conservative substitutions or additions of amino acid sequences may also be within the scope of the present disclosure, as long as the amino acid sequence has the above homology or identity and exhibits the efficacy corresponding to the above proteins.

[0037] As used herein, the term "PrdH protein" refers to a novel protein encoded by using a gene ORF, which exists between genes encoding PrdA protein and PrdB protein constituting D-proline reductase. In the present disclosure, it is referred to as PrdH. Further, depending on the type or characteristics of the strain having D-proline reductase activity, the PrdH protein may overlap with a portion of PrdA or PrdB, and the stop codon of PrdH may be located after the start codon of PrdB, but is not limited thereto.

[0038] The PrdH protein can be co-expressed with the PrdA protein and the PrdB protein to induce precise self-cleavage of the PrdA protein and the introduction of the pyruvyl group, thereby allowing the construction of an active D-proline reductase. Specifically, any sequence can be used without restriction as long as it encodes the PrdH protein of a strain having a Stickland reaction. In other words, any sequence can be used without restriction as long as it includes a gene ORF present between genes encoding the PrdA protein and the PrdB protein of a strain having a Stickland reaction. Representative examples thereof may include PrdH proteins derived from Peptostreptococcus 630 (Clostridium difficile 630) or Lactobacillus salivarius, but are not limited thereto. The PrdH protein derived from Peptostreptococcus 630 and the PrdH protein derived from Lactobacillus salivarius have 40% homology or identity to each other, and what they have in common is a gene ORF present between genes encoding the PrdA protein and the PrdB protein derived from each of the two microorganisms. More specifically, for example, the PrdH protein may be an amino acid sequence encoded by a polypeptide sequence consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 23, but is not limited thereto.

[0039] Further, the PrdH protein of the present disclosure may include a polypeptide having at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% homology or identity with SEQ ID NO: 1 or SEQ ID NO: 23. Further, it is obvious that a PrdH protein having a partially deleted, modified, substituted, conservatively substituted or added amino acid sequence may also be within the scope of the present disclosure, as long as the amino acid sequence has the above homology or identity and exhibits the efficacy corresponding to the above protein.

[0040] As used herein, the term "homology" or "identity" refers to the degree of relatedness between two given amino acid sequences or nucleotide sequences, and can be expressed as a percentage. The terms "homology" and "identity" are often used interchangeably.

[0041] The sequence homology or identity of conservative polynucleotides or polypeptides can be determined by standard alignment algorithms and can be used with the default gap penalties established by the program used. In essence, homologous or identical sequences can hybridize under moderate or high stringency conditions such that the full length of the sequence or at least about 50%, 60%, 70%, 80% or 90% or more of the full length can hybridize. Moreover, polynucleotides containing degenerate codons in place of codons in hybridization are contemplated.

[0042] Whether any two polynucleotide or polypeptide sequences have homology, similarity or identity can be determined using known computer algorithms, such as the "FASTA" program, using, for example, the default parameters in Pearson et al. (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444, or using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453), as implemented by the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or higher) (including the GCG program package (Devereux, J. et al., Nucleic Acids Research 12:387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ETAL, J MOLEC BIOL 215]:403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ETA / .] (1988) SIAM J Applied Math 48:1073). For example, BLAST or ClustalW of the National Center for Biotechnology Information can be used to determine homology, similarity or identity.

[0043] For example, homology, similarity or identity of polynucleotides or polypeptides can be determined by comparing sequence information using a GAP computer program such as Needleman et al. (1970), J Mol Biol. 48: 443, as disclosed in Smith and Waterman, Adv. Appl. Math (1981) 2: 482. In short, the GAP program defines similarity as the number of similar aligned characters (i.e., nucleotides or amino acids) divided by the total number of characters in the shorter of the two sequences. Default parameters for the GAP program may include: (1) a binary comparison matrix (containing values ​​of 1 for identity and 0 for non-identity); and the weighted comparison matrix of Gribskov et al. (1986) Nucl. Acids Res. 14: 6745, as disclosed in Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979) (or the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each character in each gap (or a gap opening penalty of 10 and a gap extension penalty of 0.5); (3) no penalty for end gaps. Thus, as used herein, the terms "homology" or "identity" refer to the relatedness between sequences.

[0044] Further, even if the present invention describes a 'protein having an amino acid sequence of a specific SEQ ID NO', it is obvious that a protein having an amino acid sequence partially deleted, modified, substituted, conservatively substituted or added can be used in the present disclosure, as long as its activity is the same as or corresponds to the activity of a polypeptide consisting of the amino acid sequence of the corresponding SEQ ID NO. Specifically, it is not excluded to add a sequence that does not change the function of the protein before and after the amino acid sequence of the corresponding SEQ ID NO, a naturally occurring mutation, a conservative substitution or a synonymous mutation thereof. It is obvious that even if a polypeptide has such a sequence addition or mutation, it falls within the scope of the present disclosure.

[0045] As used herein, the term "conservative substitution" means that one amino acid is replaced by another amino acid with similar structural and / or chemical properties in the amino acid sequence. For example, a variant may have one or more conservative substitutions while retaining one or more biological activities. Such amino acid substitutions can generally be made based on the similarity of the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic properties of the residues. For example, positively charged (basic) amino acids include arginine, lysine, and histidine; negatively charged (acidic) amino acids include glutamic acid and aspartic acid; aromatic amino acids include phenylalanine, tryptophan, and tyrosine; and hydrophobic amino acids include alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan. Generally, conservative substitutions have little or no effect on the activity of the resulting polypeptide. Polynucleotides encoding PrdH proteins having an amino acid sequence consisting of SEQ ID NO: 1 or SEQ ID NO: 23 also fall within the scope of the present disclosure. For example, the polynucleotide can be a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 24. In a polynucleotide, various modifications may be made in the coding region due to codon degeneracy or in consideration of codon preference in the organism in which the protein is to be expressed, provided that they do not change the amino acid sequence of the protein.

[0046] Obviously, due to codon degeneracy, polynucleotides that can be translated into a protein consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 23 or a protein having homology or identity thereto may also be included. Further, probes that can be generated from a known nucleotide sequence may also be included without limitation, for example, a sequence that hybridizes with the complementary sequence of all or part of the nucleotide sequence under stringent conditions to encode a protein having the activity of the protein consisting of the amino acid sequence of SEQ ID NO: 1. The term "stringent conditions" means conditions that allow specific hybridization between polynucleotides. Such conditions are described in detail in the literature (e.g., J. Sambrook et al., supra). For example, stringent conditions may include, for example, conditions in which genes having high homology or identity, 40% or more, 85% or more, specifically 90% or more, more specifically 95% or more, more specifically 97% or more, particularly specifically 99% or more homology or identity hybridize with each other, and genes having a homology or identity lower than the above homology or identity do not hybridize with each other, or conventional washing conditions for Southern hybridization, i.e., conditions of washing once, specifically, twice or three times at a salt concentration and temperature corresponding to 60°C, 1xSSC, 0.1%SDS, specifically 60°C, 0.1xSSC, 0.1%SDS, and more specifically 68°C, 0.1xSSC, 0.1%SDS.

[0047] Although mismatches may occur between nucleotides due to the stringency of hybridization, it is required that the two nucleic acids have complementary sequences. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize to each other. For example, for DNA, adenosine is complementary to thymine, and cytosine is complementary to guanine. Therefore, the present disclosure can include not only substantially similar nucleic acid sequences, but also isolated nucleic acid fragments that are complementary to the entire sequence.

[0048] Specifically, hybridization conditions including a hybridization step at a Tm value of 55° C. and the above conditions can be used to detect polynucleotides having homology or identity. In addition, the Tm value may be 60° C., 63° C. or 65° C., but is not limited thereto, and can be appropriately controlled by a person of ordinary skill in the art according to the purpose.

[0049] The appropriate stringency for hybridization of polynucleotides depends on the length of the polynucleotides and the degree of complementation, and this variable is well known in the art (see Sambrook et al., supra, 9.50-9.51, 11.7-11.8).

[0050] As used herein, the term "enhancement of activity" means the introduction of an activity of an enzyme protein or its improvement compared to the intrinsic activity of a microorganism or the activity before modification. The "introduction" of activity means that the activity of a specific protein that the microorganism did not originally have occurs naturally or artificially. "Intrinsic activity" refers to the activity of a specific protein that the parent strain originally had before transformation when the properties of the microorganism change due to genetic variation caused by natural or artificial factors.

[0051] For example, enhancement of activity may include introduction of a foreign D-proline reductase into the host cell or through the enhancement of introduced or inherent D-proline reductase activity in its entirety.

[0052] Specifically, in the present disclosure, the enhancement of activity can be carried out in the following ways:

[0053] 1) increasing the copy number of the polynucleotide encoding the enzyme,

[0054] 2) modifying expression control sequences for increasing expression of a polynucleotide,

[0055] 3) modifying the polynucleotide sequence on the chromosome for enhancing the activity of the enzyme, or

[0056] 4) Modification by combination thereof for enhancement, but not limited thereto.

[0057] 1) The increase of the copy number of the polynucleotide can be, but is not particularly limited to, carried out in the form in which the polynucleotide is operably connected to a vector, or by inserting the polynucleotide into the chromosome of a host cell. Further, the increase of the copy number can be carried out by introducing a heterologous polynucleotide exhibiting enzymatic activity or a codon-optimized variant polynucleotide of the polynucleotide into a host cell. Any heterologous polynucleotide sequence can be used without restriction in its source or sequence, as long as it exhibits the same / similar activity as the above-mentioned enzyme. It can be carried out by a known transformation method appropriately selected by those skilled in the art, and an enzyme can be produced by expressing the introduced polynucleotide in a host cell, and as a result, its activity can be increased.

[0058] Then, 2) modification of the expression control sequence for increasing the expression of the polynucleotide can be, but not particularly limited to, carried out by deletion, insertion, non-conservative or conservative substitution or its combination of nucleotide sequence inducing modification on the sequence to further enhance the activity of the expression control sequence, or by replacing the polynucleotide sequence with a nucleotide sequence with a more active one. The expression control sequence includes, but is not particularly limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation. Specifically, a strong exogenous promoter rather than the original promoter can be connected to the upstream region of the expression unit of the polynucleotide. Examples of strong promoters can include CJ7 promoter, lysCP1 promoter, EF-Tu promoter, groEL promoter, aceA or aceB promoter, etc. Promoter and polynucleotide are operably connected to each other to improve the expression rate of the polynucleotide encoding the enzyme, but are not limited thereto.

[0059] In addition, 3) modification of the polynucleotide sequence on the chromosome can be performed, but is not particularly limited to, by deletion, insertion, non-conservative or conservative replacement of the polynucleotide sequence or a combination thereof to induce modification of the expression control sequence to further enhance the activity of the polynucleotide sequence, or by replacing the polynucleotide sequence with a polynucleotide sequence improved to have stronger activity.

[0060] Finally, 4) the method of modification for enhancement by a combination of 1) to 3) can be performed by applying one or more of the following methods: increasing the copy number of a polynucleotide encoding a protein, modifying an expression control sequence for increasing the expression of a polynucleotide, modifying a polynucleotide sequence on a chromosome, and introducing a heterologous polynucleotide exhibiting the activity of the protein or a variant polynucleotide whose codons are codon-optimized.

[0061] As used herein, the term "vector" is a DNA construct comprising a nucleotide sequence of a polynucleotide encoding a desired protein operably linked to an appropriate regulatory sequence so that the desired protein can be expressed in an appropriate host cell. The regulatory sequence may include a promoter capable of initiating transcription, any operator sequence for regulating such transcription, a sequence encoding an appropriate mRNA ribosome binding domain, and a sequence regulating the termination of transcription and translation. After the vector is transformed into an appropriate host cell, it can replicate or function independently of the host genome and can be integrated into the genome itself.

[0062] The vector used in the present disclosure is not particularly limited as long as it can replicate in a host cell, and any vector known in the art can be used. Examples of commonly used vectors may include natural or recombinant plasmids, cosmids, viruses and bacteriophages. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, Charon21A, etc. can be used as phage vectors or cosmid vectors. As plasmid vectors, pBR type, pUC type, pBluescriptII type, pGEM type, pTZ type, pCL type, pET type, etc. can be used. Specifically, pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors, etc. can be used, but are not limited thereto.

[0063] The vectors suitable for the present disclosure are not particularly limited, and known expression vectors can be used. Further, the polynucleotide encoding the desired protein can be inserted into the chromosome using a vector for intracellular chromosome insertion. The chromosome insertion of the polynucleotide can be carried out by any method known in the art, such as homologous recombination, but is not limited thereto. A selection marker may be further included to confirm the chromosome insertion. The selection marker is to select cells transformed with the vector, that is, to confirm the insertion of the desired polynucleotide, and the selection marker may include a marker that provides a selectable phenotype, such as drug resistance, auxotrophy, resistance to cytotoxic agents, or expression of surface proteins. Since only cells expressing the selection marker can survive or show different phenotypes under an environment treated with a selection agent, transformed cells can be selected.

[0064] As used herein, the term "conversion" means that a vector including a polynucleotide encoding a desired protein is introduced into a host cell in a manner such that the protein encoded by the polynucleotide is expressed in the host cell. As long as the converted polynucleotide is expressed in the host cell, it can be integrated into the chromosome of the host cell and positioned in the chromosome of the host cell, or it can exist outside the chromosome, or it has nothing to do with it. Further, the polynucleotide includes DNA and RNA encoding the target protein. The polynucleotide can be introduced in any form, as long as it can be introduced into the host cell and expressed therein. For example, the polynucleotide can be introduced into the host cell in the form of an expression cassette, which is a gene construct including all the elements required for its autonomous expression. Typically, the expression cassette includes a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal that are operably connected to the polynucleotide. Further, various factors that contribute to the effective production of the target protein can be included inside or outside the expression cassette. The expression cassette can be in the form of a self-replicable expression vector. Moreover, the polynucleotide can be introduced into the host cell as it is and can be operably connected to the sequence required for expression in the host cell, but is not limited thereto. The method for transformation may include any method for introducing nucleic acid into cells, and may be transformed by selecting appropriate standard techniques known in the art according to the host cell. For example, the method may include electroporation, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method and lithium acetate-DMSO method, but is not limited thereto.

[0065] As used herein, the term "operably linked" refers to a functional connection between a polynucleotide sequence encoding a desired protein of the present disclosure and a promoter sequence that initiates and mediates transcription of the polynucleotide. Operable connections can be prepared using gene recombination techniques known in the art, and site-specific DNA cleavage and ligation can be prepared using restriction enzymes and ligases in the art, but are not limited thereto.

[0066] Further, in addition to the microorganism expressing active D-proline reductase in which the activities of PrdA protein, PrdB protein and PrdH protein are enhanced, the specific embodiments of the present disclosure also provide a microorganism expressing active D-proline reductase in which the activity of one or more proteins selected from PrdD, PrdE and PrdE2 is enhanced.

[0067] Further, in addition to the microorganism expressing active D-proline reductase in which the activities of PrdA protein, PrdB protein and PrdH protein are enhanced, the specific embodiments of the present disclosure also provide a microorganism expressing active D-proline reductase in which the activity of one or more proteins selected from PrdC, PrdG and PrdF is enhanced.

[0068] "PrdD protein, PrdE protein, PrdE2 protein, PrdC protein, PrdG protein and PrdF protein" refer to the proteins of the Prd operon that constitute the D-proline reductase. Specifically, in addition to the PrdA and PrdB proteins that constitute the D-proline reductase, the proteins that constitute the Prd operon are called PrdDEE2CGFR. The most well-known prd operon is present in Clostridium sticklandii strains, and the protein name is based on the construction of the operon (NCBI GenBank: FP565809.1) of Clostridium sticklandii (Jackson et al., J. Bacteriol., 2006, 188, 8487-8495).

[0069] The functions of the proteins constituting the Prd operon have not yet been elucidated, and the PrdD, PrdE and PrdE2 proteins have a high degree of sequence homology or identity with the PrdA protein. Among them, the PrdD protein has a high degree of sequence homology or identity with the β-PrdA protein, and the PrdE and PrdE2 proteins have a high degree of homology or identity with the α-PrdA protein. The sequences of the PrdD, PrdE and PrdE2 proteins can be obtained from GenBank of NCBI, which is a public database. In the present disclosure, the PrdD, PrdE and PrdE2 proteins may be PrdD, PrdE and PrdE2 proteins derived from Peptostreptococcus 630 (Clostridium difficile 630), and specifically, they may be proteins having the amino acid sequences of SEQ ID NOS: 7, 9 and 11 or the amino acid sequences encoded by the polynucleotide sequences of SEQ ID NOS: 8, 10 and 12, respectively, but are not limited thereto.

[0070] It is reported that the PrdC protein is involved in transferring electrons to D-proline reductase by utilizing NADH (Fonknechten et al., BMC Genomics, 2010, 11, 555). The PrdG protein is known as a membrane protein, but its function has not been reported. The sequence of the PrdC protein can be obtained from GenBank of NCBI, which is a public database. In the present disclosure, the PrdC and PrdG proteins may be PrdC and PrdG proteins derived from Peptostreptococcus 630 (Clostridium difficile 630), and specifically, they may be proteins having the amino acid sequences of SEQ ID NOS: 13 and 15 or the amino acid sequences encoded by the polynucleotide sequences of SEQ ID NOS: 14 and 16, respectively, but are not limited thereto.

[0071] Further, it is known that the PrdF protein, which is a proline racemase, is involved in the formation of optical isomers of proline, and it is reported that the PrdR protein has a function related to the activation of the prd operon (Bouillaut et al., J. Bacteriol., 2013, 195 (4), 844-854). The sequence of the PrdF protein can be obtained from GenBank of NCBI, which is a public database. In the present disclosure, the PrdF protein can be a PrdF protein derived from Peptostreptococcus 630 (Clostridium difficile 630), and specifically, it can be a protein having an amino acid sequence of SEQ ID NO: 17 or an amino acid sequence encoded by a polynucleotide sequence of SEQ ID NO: 18, but is not limited thereto.

[0072] As used herein, the term "microorganism" expressing active D-proline reductase refers to a microorganism expressing an active D-proline reductase consisting of an α-PrdA that binds pyruvyl, which is obtained by precise self-cleavage of PrdA protein, β-PrdA and PrdB. "Microorganism" can include any of prokaryotic microorganisms and eukaryotic microorganisms, as long as it can produce active D-proline reductase. For example, the microorganism can include microorganisms of the genus Escherichia, Erwinia, Serratia, Providencia, Corynebacterium and Brevibacterium. An example of an Escherichia microorganism can be Escherichia coli, but is not limited thereto.

[0073] The active D-proline reductase-producing microorganism of the genus Escherichia capable of expressing the polypeptide having D-proline reductase activity of the present disclosure may include all microorganisms capable of expressing the polypeptide by various known methods except for the above vector introduction.

[0074] Another aspect of the present disclosure provides a method for producing active D-proline reductase, the method comprising the steps of culturing a microorganism expressing active D-proline reductase in a culture medium, and recovering the active D-proline reductase from the microorganism or the culture medium.

[0075] The "microorganism expressing active D-proline reductase" is the same as described above.

[0076] "Cultivation" means that the microorganism is grown under properly controlled environmental conditions. The cultivation process disclosed herein can be carried out according to appropriate culture media and culture conditions known in the art. According to the selected strain, the skilled person can easily regulate and use the cultivation process. The step of cultivating the microorganism can be, but is not particularly limited to, carried out by known batch culture, continuous culture, fed-batch culture, etc. In this regard, the culture conditions are not particularly limited, but can be adjusted to an optimal pH (e.g., pH 5 to 9, specifically pH 6 to 8, and most specifically pH 6.8) by using an alkaline compound (e.g., sodium hydroxide, potassium hydroxide or ammonia) or an acidic compound (e.g., phosphoric acid or sulfuric acid). Moreover, defoamers such as fatty acid polyethylene glycol esters can be used during the culture to suppress foam generation. In order to keep the culture in an aerobic state, oxygen or oxygen-containing gas can be injected into the culture. In order to keep the culture in an anaerobic or microaerobic state, gas can not be injected, or nitrogen, hydrogen or carbon dioxide gas can be injected into the culture. The culture temperature can be maintained at 20°C to 45°C, and specifically maintained at 25°C to 40°C, but is not limited thereto. The culture may be continued, specifically for about 10 hours to about 160 hours, but not limited thereto, until the desired material of the desired amount is obtained. In addition, in the culture medium to be used, carbon sources, such as sugars and carbohydrates (e.g., glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose), oils (e.g., soybean oil, sunflower seed oil, peanut oil and coconut oil), fatty acids (e.g., palmitic acid, stearic acid and linoleic acid), alcohols (e.g., glycerol and ethanol) and organic acids (e.g., acetic acid) may be used alone or in a mixture thereof, but not limited thereto. Nitrogen sources, such as nitrogen-containing organic compounds (e.g., peptone, yeast extract, gravy, malt extract, corn steep liquor, soybean meal and urea) or inorganic compounds (e.g., ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate) may be used alone or in a mixture thereof, but not limited thereto. Potassium sources, such as monopotassium phosphate, dipotassium hydrogen phosphate or sodium salts corresponding thereto, may be used alone or in a mixture thereof, but not limited thereto. In addition, other necessary growth-promoting substances may be included in the culture medium, including metal salts (eg, magnesium sulfate or iron sulfate), amino acids, and vitamins.

[0077] Under optimized culture medium and culture conditions known in the art, a person skilled in the art can easily determine a method for producing active D-proline reductase. The step of recovering active D-proline reductase can be performed using a suitable method known in the art. For example, centrifugation, filtration, distillation, ion exchange chromatography, crystallization, HPLC, etc. can be used, but are not limited thereto.

[0078] Further, the recovery step may include a purification process and may be performed using appropriate methods known in the art. Thus, the active D-proline reductase to be collected may be in a purified form or in a fermentation broth of a microorganism containing the active D-proline reductase.

[0079] Still another aspect of the present disclosure provides a method for converting D-proline or an analog thereof by a reduction method using a microorganism expressing active D-proline reductase or an active D-proline reductase produced thereby.

[0080] Specifically, the method can be a method for producing one or more selected from 5-aminovaleric acid (5-AVA), γ-aminobutyric acid (GABA) and 5-amino-4-hydroxyvaleric acid using a microorganism expressing active D-proline reductase or an active D-proline reductase produced thereby.

[0081] D-proline analogs are substances having a structure similar to D-proline, and include all analogs in which the carboxyl group, the α carbon and the amino group are sequentially connected, and a ring structure including the α carbon and the amino group is formed regardless of the size of the ring, and which can be reduced by the active D-proline reductase of the present disclosure. Specifically, the D-proline analog can be selected from D-azetidine-2-carboxylic acid, trans-4-hydroxy-D-proline and cis-4-hydroxy-D-proline, but is not limited thereto.

[0082] Further, being reduced by active D-proline reductase means that the bond between the α carbon and the amino group in the structure of D-proline or its analog is broken, and as a result, the ring structure is released. Specifically, D-proline can be converted into 5-aminovaleric acid (5-AVA) by active D-proline reductase. Further, compared with D-proline, due to the lack of a carbon atom, D-azetidine-2-carboxylic acid has a 4-membered ring structure, and when converted by active D-proline reductase, gamma-aminobutyric acid (GABA) can be produced. Further, when cis-4-hydroxy-D-proline or trans-4-hydroxy-D-proline formed by increasing a hydroxyl group (-OH) on the ring structure of D-proline is converted by active D-proline reductase, 5-amino-4-hydroxyvaleric acid can be produced, but is not limited thereto.

[0083] Still another aspect provides a PrdH protein having the activity of converting an inactive D-proline reductase into an active D-proline reductase while being co-expressed with a PrdA protein and a PrdB protein.

[0084] The "PrdA protein", "PrdB protein", "PrdH protein" and "active D-proline reductase" are the same as described above.

[0085] As used herein, the term "coexpression" means that the expression of two or more proteins or the expression of genes encoding two or more proteins occurs simultaneously. Those skilled in the art can easily determine the method of expressing the gene or protein by methods known in the art.

[0086] As used herein, the term "converting an inactive D-proline reductase into an active D-proline reductase" means converting a D-proline reductase in an inactive state into an active D-proline reductase. This means that the inactive D-proline reductase is converted into an active D-proline reductase composed of α-PrdA bound to pyruvyl obtained by precise self-cleavage of PrdA protein, β-PrdA and PrdB. "Inactive D-proline reductase" means a D-proline reductase in which self-cleavage of the PrdA protein does not occur, or even if self-cleavage of the PrdA protein occurs, including α-PrdA and β-PrdA that are not bound to pyruvyl, or the protein of PrdA or PrdB is not expressed, or even if expressed, the protein of PrdA or PrdB is inactive.

[0087] Still another aspect provides a method for producing a microorganism expressing active D-proline reductase, the method comprising the steps of transforming a host cell with an expression cassette comprising a prdA gene or prdA and prdH genes, and transforming a host cell with an expression cassette comprising a prdB gene or prdB and prdH genes.

[0088] The "PrdA protein", "PrdB protein", "PrdH protein", "expression cassette", "active D-proline reductase" and "microorganism expressing active D-proline reductase" are the same as described above.

[0089] Example

[0090] Hereinafter, the present disclosure will be described in more detail with reference to examples. However, these examples are only for illustrating the present disclosure, and the scope of the present disclosure is not intended to be limited by these examples.

[0091] Example 1: Expression of PrdA and PrdH proteins

[0092] 1-1: Gene selection for PrdA protein expression

[0093] To express the PrdA protein, the amino acid sequence (Q17ZY9, UniProtKB, SEQ ID NO: 3) of the D-proline reductase PrdA protein derived from Peptostreptococcus 630 (Clostridium difficile 630), which is known to be a representative strain with Stickland reaction, was tested. The nucleotide sequence of the D-proline reductase PrdA protein (CD630_32440, NCBI GeneBank AM180355.1, SEQ ID NO: 4) was used to construct an expression vector.

[0094] 1-2: Construction of a vector expressing PrdA (pETDuet_H6-prdA-H6)

[0095] A 6X histidine tag (H6) for Western blot analysis was incorporated into both ends of the nucleotide sequence, and a gene having NdeI and XhoI restriction enzyme sequences at the amino and carboxyl termini was synthesized. The synthesized gene and pETDuet-1 vector were specifically digested with NdeI / XhoI restriction enzymes, respectively, and each gene fragment was then obtained by separation on an agarose gel. A vector (pETDuet_H6-prdA-H6) expressing PrdA was constructed by an enzymatic reaction of T4 ligase.

[0096] 1-3: Construction of an expression vector with a site-directed mutation at the self-cleavage site of the PrdA protein (pETDuet_H6-prdA(C421A)-H6)

[0097] Alanine scanning was applied to the amino acid at position 421, which is known to be a site where self-cleavage of the PrdA protein occurs. Site-directed mutagenesis was performed to replace (C421A) cysteine, which is the amino acid at position 421, with alanine. To this end, the constructed pETDuet_H6-prdA-H6 vector and primers of SEQ ID NOS: 25 and 26 designed for the C421A mutation (Table 1) were added to the Pfu PCR premix to amplify the gene. At this time, the PCR reaction was subjected to 30 cycles of denaturation at 94°C for 1 minute, annealing at 55°C for 1 minute, and extension at 72°C for 10 minutes. The PCR product was treated with DpnI (37°C, 3 hours) and transformed into Escherichia coli (DH5α). The transformed Escherichia coli was cultured to obtain a strain, and the plasmid vector was isolated therefrom. Sequencing was performed to obtain the pETDuet_H6-prdA (C421A) -H6 vector.

[0098] [Table 1]

[0099] Serial Number Primers Sequence (5'-3') 25 PrdA(C421A)-F <![CDATA[GGTATCCATGCATTAACT GCC ATAGGACCTGCATC AAAAG]]> 26 PrdA(C421A)-R <![CDATA[CTTTTGATGCAGGTCCTAT GGC AGTTAATGCAT GGA TAC C]]>

[0100] *Underlined part: C421A mutation site

[0101] 1-4: Construction of an expression vector for co-expression of PrdA and PrdH proteins (pETDuet_prdH_H6-prdA-H6)

[0102] In order to induce self-cleavage of the PrdA protein, co-expression was attempted by using a novel protein (amino acid sequence: Q17ZY5, UniProtKB, SEQ ID NO: 1 / nucleotide sequence: CD630_32430, NCBI GeneBank AM180355.1, SEQ ID NO: 2; hereinafter, it is referred to as the PrdH protein) encoded by a gene ORF present between genes encoding PrdA and PrdB, which are structural proteins in the protein constituting the prd operon derived from Peptostreptococcus 630 (Clostridium difficile 630). For this purpose, a gene having a restriction enzyme sequence of the NcoI / NotI combination at the amino and carboxyl termini of the nucleotide sequence, respectively, was synthesized. The synthesized prdH gene and the previously constructed pETDuet_H6-prdA-H6 vector were specifically digested with NcoI / NotI restriction enzymes, respectively, and then each gene fragment was obtained by separation on an agarose gel. An expression vector (pETDuet_prdH_H6-prdA-H6) capable of co-expressing PrdA and PrdH proteins was constructed through an enzymatic reaction catalyzed by T4 ligase.

[0103] 1-5: Identification of PrdA protein expression and PrdA self-cleavage by constructing three expression vectors

[0104] In the next step, the constructed pETDuet_H6-prdA-H6, pETDuet_H6-prdA(C421A)-H6 or pETDuet_prdH_H6-prdA-H6 expression vector was transformed into Escherichia coli BL21(DE3), and then inoculated into LB medium (50 ml) containing ampicillin antibiotic (0.1 mg / ml), followed by cultivation at 37°C and 200 rpm.

[0105] To induce overexpression of the desired protein, 600 When the value reached 0.5 to 0.6, 0.1 mM isopropyl β-D-1-thiogalactopyranoside (hereinafter referred to as IPTG) was added.

[0106] Further, in order to induce self-cleavage of the PrdA protein by binding to a substrate, Escherichia coli transformed with the pETDuet_H6-prdA-H6 vector was cultured in a culture medium in the presence or absence of the substrate D-proline (10 mM).

[0107] Thereafter, the culture was further performed for 16 hours under shaking conditions at 200 rpm at 30° C. or under static culture conditions at 30° C. The static culture conditions were performed by omitting the shaking process to reduce nonspecific degradation of the expressed PrdA protein.

[0108] In order to examine the expression of the recombinant PrdA protein, the obtained strain was disrupted and centrifuged (15000 rpm, 4°C and 10 minutes) to separate the supernatant, followed by SDS-PAGE analysis and Western blot analysis. The results of the analysis confirmed that the desired protein ( 67.6 kDa) having a molecular weight equal to the theoretical molecular weight of the PrdA protein was expressed. Figure 2 ). However, the protein was expressed in the form of pro-PrdA protein, which cannot self-cleave and is an inactive form of PrdA protein. For this reason, no additional protein production was found (α-PrdA, 21.9 kDa and β-PrdA, 44.7 kDa). Further, non-specifically cleaved protein bands were found in the results of Western blotting, indicating that much protein degradation occurred due to the structural instability of the pro-PrdA protein that was not self-cleaved ( Figure 2 , lane 2). Furthermore, the expression pattern of the PrdA (C421A) variant protein prepared by replacing the cysteine ​​at position 421 of the PrdA protein, which is known to be a site of self-cleavage, with alanine was the same as that of the wild-type PrdA, also confirming that the PrdA protein did not self-cleave by an independent mechanism ( Figure 2 , Lane 3). Further, when D-proline ( Figure 2 , lane 4) to induce self-cleavage of PrdA protein by substrate binding or when PrdA protein was co-expressed with PrdH protein, self-cleavage of PrdA protein did not occur (Figure, lane 5).

[0109] When the PrdA protein was expressed alone, static culture was performed without a shaking process in order to reduce nonspecific degradation of the expressed protein, and the expression pattern of the PrdA protein was analyzed. In this case, the degradation of the protein itself was improved due to its relatively low expression level, but self-cleavage did not occur ( Figure 3 , lanes 3 and 4). In detail, a cleaved protein with a size similar to that of the β-PrdA protein was found, but the α-PrdA protein was not found, indicating that the cleaved protein was a protein produced by nonspecific cleavage. These results are consistent with those of the prior art (Korean Patent Publication No. 2015-0029526; Bednarski et al., Eur. J. Biochem., 2001, 268, 3538-3544).

[0110] Example 2: Expression of PrdB protein

[0111] 2-1: Gene selection for PrdB protein expression

[0112] For PrdB protein expression, the amino acid sequence (Q17ZY6, UniProtKB, SEQ ID NO: 5) of the D-proline reductase PrdB protein derived from Peptostreptococcus 630 (Clostridium difficile 630), which is known to be a representative strain with Stickland reaction, was tested. The nucleotide sequence of the protein (CD630_32410, NCBI GeneBankAM180355.1, SEQ ID NO: 6) was used to construct an expression vector.

[0113] 2-2: Construction of PrdB expression vector (pCDFDuet_prdB-H6)

[0114] The gene was synthesized by incorporating a 6X histidine tag (H6) for Western blot analysis at the carboxyl terminus of the nucleotide sequence and including NdeI and XhoI restriction enzyme sequences at the amino and carboxyl termini, respectively. The synthesized gene and pCDFDuet-1 vector were specifically digested with NdeI / XhoI restriction enzymes, respectively, and each gene fragment was then obtained by separation on an agarose gel. The vector (pCDFDuet_prdB-H6) expressing PrdB was constructed by the enzymatic reaction of T4 ligase.

[0115] 2-3: Construction of a vector for introducing selenocysteine ​​into PrdB protein

[0116] The PrdB protein is known as a selenoprotein. In other words, since selenocysteine ​​is included in the amino acid sequence of the PrdB protein and selenocysteine ​​is a non-natural amino acid, there are technical limitations, that is, it is difficult to introduce by general protein synthesis methods. Therefore, in the present disclosure, the introduction of selenocysteine ​​of the PrdB protein was attempted by introducing the sel operon system (selABC) (Su et al., Nucleic Acids Res., 2005, 33 (8), 2486-2492) as a known technology.

[0117] 2-3-1: Vector introduced by SelAB (pACYCDuet_selB / pACYCDuet_selA_selB)

[0118] To this end, the SelA protein (amino acid sequence: Q182I2, UniProtKB / nucleotide sequence: CD630_24950, NCBI GeneBank AM180355.1) and SelB protein (amino acid sequence: Q182I0, UniProtKB / nucleotide sequence: CD630_24930, NCBI GeneBank AM180355.1) derived from Peptostreptococcus 630 (Clostridium difficile 630) were used, and such genes were synthesized so that they had restriction enzyme sequences of NcoI / NotI and NdeI / XhoI combination at the amino and carboxyl termini, respectively.

[0119] Next, commercially available pACYCDuet-1 plasmid vector (Novagene) and selB gene were processed with the combination of NdeI / XhoI restriction enzymes, respectively, and separated on agarose gel. Then, by T4 ligase reaction, pACYCDuet_selB vector was constructed. By the other restriction enzyme reaction of NdeI / XhoI combination, selA gene was inserted into the vector (pACYCDuet_selB). Finally, pACYCDuet_selA_selB vector was constructed.

[0120] 2-3-2: vector introduced by selC (pCDFDuet_prdB-H6_P selC -selC)

[0121] The selC gene encodes a tRNA specific for selenocysteine, and is synthesized by including the selC gene (nucleotide sequence: CDIF630_02727, NCBI GeneBank CP010905.1) derived from peptostreptococcus 630 (clostridium difficile 630) and 150 additional nucleotides from the amino terminus and 250 nucleotides from the carboxyl terminus to include the intrinsic promoter and terminator of selC, and finally the XbaI restriction enzyme sequences at both ends. The selC gene thus obtained and the previously constructed pCDFDuet_prdB-H6 vector were treated with the XbaI restriction enzyme and then separated on an agarose gel. By T4 ligase reaction, the pCDFDuet_prdB-H6_PselC-selC vector was finally constructed.

[0122] 2-4: Identification of PrdB protein expression by three constructed expression vectors

[0123] 1) Expression of PrdB protein alone

[0124] The pCDFDuet_prdB-H6 vector prepared in Example 2-2 was transformed into Escherichia coli BL21 (DE3), and cultured in LB medium (50 ml) containing antibiotics (50 μg / ml of spectinomycin) (37° C., 200 rpm).

[0125] 2) Co-expression of PrdB protein and selC

[0126] pCDFDuet_prdB-H6-P prepared in Example 2-3 selC The _selC vector was transformed into Escherichia coli BL21 (DE3) and cultured in the same manner as 1).

[0127] 3) Co-expression of PrdB and selAB proteins

[0128] A combination of the pCDFDuet_prdB-H6 prepared in Example 2-2 and the pACYCDuet_selA_selB vector prepared in Example 2-3 was transformed into Escherichia coli BL21(DE3), and cultured in the same manner as in 1).

[0129] 4) Co-expression of PrdB protein and selABC

[0130] pCDFDuet_prdB-H6-P prepared in Example 2-3 selC The combination of pACYCDuet_selA_selB vectors was transformed into Escherichia coli BL21 (DE3) and cultured in the same manner as in 1).

[0131] To induce overexpression of the desired protein, 600 When the value reached 0.5 to 0.6, 0.1 mM IPTG was added. Further, in order to supply the selenium required for biosynthesis and selenocysteine ​​introduction, 10 μM sodium selenite was supplied or not supplied, and then further cultured for 16 hours. Each obtained Escherichia coli strain was destroyed, and each supernatant was centrifuged and then subjected to Western blot analysis.

[0132] The results of the analysis showed that when the PrdB protein was expressed alone, the PrdB protein was expressed at a very low level due to the low efficiency of selenocysteine ​​incorporation ( Figure 4 , lanes 1 and 2), and when PrdB protein and selC were co-expressed ( Figure 4 , lanes 3 and 4) or when PrdB and SelAB proteins were co-expressed ( Figure 4 , lanes 5 and 6), the same results were observed ( Figure 4However, when PrdB protein and selABC genes were co-expressed, the expression level of PrdB protein increased significantly ( Figure 4 , lane 7), indicating that the unnatural amino acid selenocysteine ​​is effectively incorporated into the PrdB protein due to the action of SelA and SelB proteins constituting the sel operon and SelC as a selenocysteine-specific tRNA. Furthermore, compared with the case without the addition of sodium selenite (lane 7), the addition of sodium selenite ( Figure 7 , lane 8; final concentration: 10 μM) further increased the expression level of PrdB protein, indicating that constructing a system for effectively incorporating selenocysteine ​​is the main factor in increasing the expression level of PrdB protein.

[0133] Example 3: Functional verification of PrdH protein and evaluation of D-proline reductase activity including expression of PrdH protein estimate

[0134] 3-1: Expression of D-proline reductase protein to verify PrdH function

[0135] Based on the information confirmed above, the expression of D-proline reductase was attempted, and for this purpose, the following combinations of vectors were evaluated.

[0136] 1) Co-expression of PrdA and PrdB proteins

[0137] Co-expression of the previously constructed vector expressing PrdA protein (pETDuet_H6-prdA-H6) and the vector expressing PrdB protein (pCDFDuet_prdB-H6-P selC The three expression vectors were transformed into Escherichia coli BL21 (DE3) and cultured in LB medium (50 ml) containing antibiotics (0.1 mg / ml ampicillin, 50 μg / ml spectinomycin and 30 μg / ml chloramphenicol) (37°C, 200 rpm).

[0138] 2) Co-expression of PrdA, PrdB and PrdH proteins

[0139] The previously constructed vectors for co-expression of PrdA and PrdH (pETDuet_prdH_H6-prdA-H6) and expression of PrdB protein (pCDFDuet_prdB-H6-P selC The co-expression was performed by combining pACYCDuet_selC and pACYCDuet_selA_selB vectors. The culture method was performed in the same manner as 1).

[0140] 3) Co-expression of PrdA(C421A), PrdB and PrdH proteins

[0141] The previously constructed vectors for co-expressing PrdA(C421A) and PrdH proteins (pETDuet_prdH_H6-prdA(C421A)-H6) and PrdB proteins (pCDFDuet_prdB-H6-P selC The co-expression was performed by combining pACYCDuet_selC and pACYCDuet_selA_selB vectors. The culture method was performed in the same manner as 1) and 2).

[0142] To induce overexpression of the desired protein, 600 When the value reached 0.5 to 0.6, 0.1 mM IPTG was added to each culture medium, 10 μM sodium selenite was supplied, and then cultured for further 16 hours.

[0143] 3-2: Identification of self-cleavage of PrdA protein by introduction of PrdH protein - Western blot analysis

[0144] The Escherichia coli cells of each culture medium obtained in Example 3-1 were disrupted and centrifuged to separate the supernatant, followed by Western blot analysis.

[0145] The results of the analysis showed that when only PrdA and PrdB proteins were co-expressed, no self-cleavage of PrdA protein was observed ( Figure 5 , lane 1). However, when PrdH protein was co-expressed with PrdA and PrdB proteins, the inactive form of PrdA protein (Pro-PrdA protein) disappeared and another protein band was formed ( Figure 5 , lane 2).

[0146] To confirm whether the above experimental results are due to the intrinsic self-cleavage mechanism of PrdA protein, the cysteine ​​at position 421, which is known to be the self-cleavage site of PrdA protein, was replaced with alanine (C421A), and PrdB and PrdH proteins were co-expressed. As a result, Pro-PrdA protein was maintained, and no cleaved protein was observed ( Figure 5 , lane 3), indicating that the additional protein is the protein generated by the specific cleavage of cysteine ​​at position 421 of the PrdA protein.

[0147] Therefore, it was confirmed that the PrdH protein is an essential protein for the self-cleavage of the PrdA protein and is an auxiliary protein that plays an important role in ensuring the activity of the PrdA protein.

[0148] In addition, based on the results of the previous examples, in which even when the PrdA protein and the PrdH protein were co-expressed, self-cleavage of the PrdA protein did not occur (Example 1; Figure 2, lane 5), confirming that the PrdH protein and the PrdB protein must exist simultaneously to induce the self-cleavage of the PrdA protein, which indicates that the PrdA protein and the PrdB protein preferentially form a complex at a predetermined level or higher, and then the cleavage process of the PrdH protein occurs.

[0149] 3-3: Evaluation of D-proline reductase activity of co-expressed PrdH protein – TLC analysis

[0150] The final OD of the E. coli cells obtained in 3-1 was adjusted to 50, followed by centrifugation. After preliminary washing, the E. coli cells were diluted with 1 mL of 0.1 M phosphate buffer (pH 8.0). Next, each 200 ul of the diluted sample was distributed, and DTT (final concentration was 25 mM) and D-proline (final concentration was 10 mM) were added and reacted for 6 hours, followed by TLC analysis.

[0151] The strain co-expressing PrdA, PrdB and PrdH proteins showed the formation of a spot corresponding to 5-aminovaleric acid (5-AVA) on TLC ( Figure 6 , Lane 1). In the absence of PrdH protein, no activity was observed ( Figure 6 , lane 2), indicating that due to the absence of PrdH protein, self-cleavage of PrdA protein did not occur, and therefore, no D-proline reductase activity was observed.

[0152] The strain co-expressing PrdA, PrdB, and PrdH proteins was designated CC04-9007 and then deposited in the Korean Collection of Microorganisms (KCCM), an international depository under the Budapest Treaty, on February 2, 2017, with the accession number KCCM11963P.

[0153] Example 4. Verification of the universal application of PrdH protein

[0154] 4-1: Selection of strains for validating the universal application of PrdH protein

[0155] In order to verify that the PrdH protein is an essential auxiliary protein that is generally applied to the self-cleavage of the PrdA protein, it was examined whether the PrdH protein (hereinafter referred to as LsPrdH) is involved in the self-cleavage of the PrdA protein derived from Lactobacillus salivarius (hereinafter referred to as LsPrdA), which is a strain known to have a Stickland reaction in addition to Peptostreptococcus 630.

[0156] 4-2: Construction of a vector expressing LsPrdA (pETDuet_H6-LsprdA-H6)

[0157] The gene was synthesized by incorporating a 6X histidine tag (H6) for Western blot analysis into both ends of the nucleotide sequence of the LsPrdA protein (amino acid sequence: E1JLY6, UniProtKB, SEQ ID NO: 19 / nucleotide sequence: HMPREF9269_1797, NCBI GeneBank AEBA01000066, SEQ ID NO: 20), and by including NdeI and XhoI restriction enzyme sequences at the amino and carboxyl termini, respectively. The pETDuet-1 vector and the synthesized gene were digested with a combination of NdeI / XhoI restriction enzymes, and then each gene fragment was obtained by separation on an agarose gel. The pETDuet_H6-LsprdA-H6 expression vector was constructed by an enzymatic reaction of T4 ligase.

[0158] 4-3: Construction of a vector for co-expression of LsPrdA and LsPrdH proteins (pETDuet_LsprdH_H6-LsprdA-H6)

[0159] In addition, the restriction enzyme sequence of NcoI / NotI combination was added to both ends of the nucleotide sequence of LsPrdH protein (amino acid sequence: E1JLY7, UniProtKB, SEQ ID NO: 23 / nucleotide sequence: HMPREF9269_1798, NCBIGeneBank AEBA01000066.1, SEQ ID NO: NO: 24), and then synthesized. The constructed pETDuet_H6-LsPrdA-H6 expression vector was digested with the combination of NcoI / NotI restriction enzymes, and the gene fragment was obtained by separation on agarose gel. The pETDuet_LsprdH_H6-LsprdA-H6 expression vector was constructed by the enzymatic reaction of T4 ligase.

[0160] 4-4: Construction of a vector expressing LsPrdB (pCDFDuet_LsprdB(U151C)-H6)

[0161] A 6X histidine tag (H6) for Western blot analysis was incorporated into the carboxyl terminus of the corresponding gene of the PrdB protein derived from Lactobacillus salivarius (hereinafter referred to as LsPrdB) (amino acid sequence: E1JLY8 and E1JLY9, UniProtKB, SEQ ID NO: 21 / nucleotide sequence: HMPREF9269_1799 and HMPREF9269_1800, NCBI GeneBankAEBA01000066.1, SEQ ID NO: 22); on the sequence database, the stop codon (UAG) sequence present in the LsPrdB protein was not recognized as a sequence for selenocysteine ​​introduction but as a stop codon for protein expression, so the sequence was expressed as two proteins or nucleotide sequences, and therefore, an expression vector was constructed by evaluating the two nucleotide sequences and the sequence between the two nucleotide sequences as the nucleotide sequence of the LsPrdB protein. ). Furthermore, in order to prevent the codon for selenocysteine ​​(UGA) introduced for efficient expression of PrdB protein from being recognized as a stop codon, the codon was replaced with a cysteine ​​codon (UGT), and sequences for NdeI and XhoI restriction enzymes were added to the amino and carboxyl termini, respectively.

[0162] On this basis, the pCDFDuet-1 vector and the synthesized gene were digested with a combination of NdeI / XhoI restriction enzymes, respectively, and then each gene fragment was obtained by separation on agarose gel and enzymatic reaction with T4 ligase to construct the pCDFDuet_LsprdB(U151C)-H6 expression vector.

[0163] 4-5: Identification of self-cleavage of LsPrdA protein by introduction of LsPrdH protein - Western blot analysis

[0164] The constructed vectors expressing LsPrdA protein (pETDuet_H6-LsprdA-H6) and LsPrdB protein (pCDFDuet_LsprdB(U151C)-H6) or the vectors expressing LsPrdA and LsPrdH proteins (pETDuet_LsprdH_H6-LsprdA-H6) and LsPrdB protein (pCDFDuet_LsprdB(U151C)-H6) were co-expressed. The two combinations of expression vectors were transformed into Escherichia coli BL21 (DE3) and cultured in LB medium containing antibiotics (0.1 mg / ml ampicillin, 50 μg / ml spectinomycin) (37°C, 200 rpm). In order to induce overexpression of the desired protein, when OD 600When the value reached 0.5 to 0.6, 0.1 mM IPTG was added, and then cultured for further 16 hours. Each of the obtained Escherichia coli strains was disrupted, and centrifugation was performed to separate each supernatant, followed by Western blot analysis.

[0165] As a result of the experiment, when LsPrdA protein and LsPrdB(U151C) protein were co-expressed, the non-cleaved form of LsPrdA protein (Pro-LsPrdA protein) and LsPrdB protein were expressed, and non-specific degradation of LsPrdA protein was observed ( Figure 7 , lane 1). In contrast, when co-expressed with LsPrdH protein, Pro-LsPrdA protein decreased, and additional protein bands were observed, indicating the self-cleavage phenomenon of LsPrdA protein ( Figure 7 , lane 2). The LsPrdH protein has about 55% amino acid sequence homology with the previously obtained PrdH protein, but has the same characteristics: they are encoded by a gene ORF located between the prdA gene and the prdB gene on the genome.

[0166] Thus, it has been demonstrated that the two proteins (PrdH and LsPrdH proteins) present at similar positions on the genome have the same function even though they have a relatively low level of sequence homology, and it has also been demonstrated that, regardless of the strain species and sequence homology, the PrdH protein has a universal function of inducing self-cleavage of the PrdA protein, which is an essential step for the production of active D-proline reductase.

[0167] Example 5: Evaluation of the activity of fully expressed proteins from the D-proline reductase operon - co-expression with PrdDEE2 protein Express

[0168] To evaluate the influence of other proteins in the prd operon on D-proline reductase (whose activity had been confirmed), additional co-expressions were performed. As a first step, co-expression of the PrdDEE2 protein was performed.

[0169] 5-1: Construction of a vector for co-expression of PrdA, PrdH and PrdDEE2 proteins (pETDuet_prdH_prdADEE2)

[0170] In order to co-express with PrdA protein, PrdD protein (amino acid sequence: Q17ZY7, UniProtKB, SEQ ID NO: 7 / nucleotide sequence: CD630_32400, NCBI GeneBank AM180355.1, SEQ ID NO: 8), PrdE protein (amino acid sequence: Q17ZY2, UniProtKB, SEQ ID NO: 9 / nucleotide sequence: CD630_32390, NCBI GeneBank AM180355.1, SEQ ID NO: 10) and PrdE2 protein (amino acid sequence: Q17ZY3, UniProtKB, SEQ ID NO: 11 / nucleotide sequence: CD630_32380, NCBI GeneBank AM180355.1, SEQ ID NO: 12) were derived from Peptostreptococcus 630 (Clostridium difficile 630). NO: 12), a ribosome binding site was added between each gene, and the restriction enzyme sequence of NdeI / XhoI combination was added to both ends for synthesis (prdADEE2). In detail, the pETDuet_prdH_H6-prdA-H6 expression vector and the synthetic prdDEE2 gene previously constructed in Example 1-4 were digested with the combination of restriction enzymes NdeI / XhoI, and then the gene fragments were obtained by separation on agarose gel. The pETDuet_prdH_prdADEE2 expression vector was constructed by the enzymatic reaction of T4 ligase.

[0171] 5-2: Co-expression of PrdA, PrdB, PrdH and PrdDEE2 proteins and verification of enhanced D-proline reductase activity-TLC analysis

[0172] Co-expression of a vector expressing PrdADEE2 and PrdH proteins (pETDuet_prdH_prdADEE2) and a vector expressing PrdB protein (a combination of pCDFDuet_prdB-PselC_selC and pACYCDuet_selA_selB vectors) was performed.

[0173] The three expression vectors were transformed into Escherichia coli BL21 (DE3) and cultured in LB medium containing antibiotics (0.1 mg / ml ampicillin, 50 μg / ml spectinomycin and 30 μg / ml chloramphenicol) (37°C, 200 rpm). In order to induce overexpression of the desired protein, the expression of the protein was induced when OD 600When the value reached 0.5 to 0.6, 0.1 mM IPTG was added, and 10 μM sodium selenite was supplied, and then further cultured for 16 hours. The final OD of the obtained E. coli cells was adjusted to 50, followed by centrifugation. After the initial washing, the E. coli cells were diluted with 1 mL of 0.1 M phosphate buffer (pH 8.0).

[0174] Next, the diluted sample was dispensed at 200 ul each, and DTT (final concentration: 25 mM) and D-proline (final concentration: 10 mM) were added and allowed to react for 6 hours, followed by TLC analysis.

[0175] As a result, compared with the combination with PrdAHB protein, the combination with PrdAHBDEE2 showed a relatively large 5-aminovaleric acid spot on TLC, and the initial reaction rate of D-proline reductase was also fast ( Figure 6 , Lane 3). These results indicate that PrdDEE2 protein induces the enhancement of D-proline reductase activity.

[0176] Example 6: Additional expression of PrdC protein and verification of enhanced D-proline reductase activity

[0177] Next, co-expression of PrdC protein was performed. It is known that D-proline reductase performs the conversion reaction by consuming NADH, and PrdC participates in NADH-dependent electron transfer. Therefore, PrdC protein may contribute to the electron transfer of D-proline reductase. In order to examine the effect of PrdC protein, experiments were performed in the presence or absence of the reducing agent DTT.

[0178] 6-1: Construction of a vector for expressing PrdC protein (pACYCDuet_selA-prdC_selB)

[0179] In order to add the PrdC protein (amino acid sequence: Q17ZZ2, UniProtKB, SEQ ID NO: 13 / nucleotide sequence: CD630_32470, NCBI GeneBank AM180355.1, SEQ ID NO: 14) derived from Peptostreptococcus 630 (Clostridium difficile 630) to the existing D-proline reductase expression system, a vector capable of co-expressing SelA and SelB proteins was constructed. A ribosome binding site was inserted between the selA and prdC genes, and restriction enzyme sequences of the NcoI / NotI combination were added to both ends for synthesis (selA-prdC). The previously constructed pACYCDuet_selA_selB expression vector and the synthesized selA-prdC gene were digested with the combination of NcoI / NotI restriction enzymes, respectively, and each gene fragment was obtained by separation on an agarose gel. By the enzymatic reaction of T4 ligase, a vector expressing pACYCDuet_selA-prdC_selB was constructed.

[0180] 6-2: Co-expression of PrdA, PrdB, PrdH and PrdC proteins and verification of enhanced D-proline reductase activity - TLC analysis

[0181] Co-expression of a vector expressing PrdADEE2 and PrdH proteins (pETDuet_prdH_prdADEE2) and a vector expressing PrdB and PrdC proteins (a combination of pCDFDuet_prdB-PselC_selC and pACYCDuet_selA-prdC_selB vectors) was performed.

[0182] The three expression vectors were transformed into E. coli BL21 (DE3) and cultured in LB medium containing antibiotics (0.1 m / ml ampicillin, 50 μg / ml spectinomycin and 30 μg / ml chloramphenicol) (37°C, 200 rpm). In order to induce overexpression of the desired protein, the expression of 600 When the value reaches 0.5-0.6, 0.1 mM IPTG is added, and 10 μM sodium selenite is supplied, and then further cultured for 16 hours. The final OD of the obtained E. coli cells is adjusted to 50, followed by centrifugation. After preliminary washing, the E. coli cells are diluted with 1 mL of 0.1 M phosphate buffer (pH 8.0). As a control group, a vector (pETDuet_prdH_prdADEE2) expressing PrdADEE2 and PrdH proteins of Example 5 and a vector (pCDFDuet_prdB-P selCThen, the diluted samples were distributed in 200ul each, and D-proline (final concentration was 10mM) was added, and reacted for 6 hours in the presence or absence of DTT (final concentration was 25mM), followed by TLC analysis.

[0183] As a result of the reaction, a relatively low reaction rate was observed compared to the addition of DTT. However, when only the PrdC protein was present, D-proline was converted into 5-aminovaleric acid ( Figure 8 , lane 2). These results suggest that the PrdC protein contributes to the electron transfer of D-proline reductase and, possibly, performs the conversion reaction by utilizing the reducing power of intracellular NADH without adding a reducing agent (DTT).

[0184] Example 7: Additional expression of prdG protein and verification of enhanced D-proline reductase activity

[0185] It is estimated that the PrdG protein is a membrane protein, but its exact function has not been reported so far.

[0186] 7-1: Construction of a vector for co-expression of PrdG and PrdB proteins (pCDFDuet_prdG_prdB-P selC _selC)

[0187] The gene was synthesized by including restriction enzyme sequences of the combination of NcoI / NotI at the amino and carboxyl termini of the nucleotide sequence of the PrdG protein derived from Peptostreptococcus 630 (Clostridium difficile 630) (amino acid sequence: Q17ZY0, UniProtKB, SEQ ID NO: 15 / nucleotide sequence CD630_32360, NCBI GeneBank AM180355.1; which is not named as PrdG protein in the sequence database, but is named as PrdG protein here based on homology with the PrdG protein of Clostridium stutzeri, SEQ ID NO: 16). The synthesized prdG gene and the pre-constructed pCDFDuet_prdB-P were digested with NcoI / NotI restriction enzymes. selC _selC vector, and then each gene fragment was obtained by separation on agarose gel. Through the enzymatic reaction of T4 ligase, a vector (pCDFDuet_prdG_prdB-PselC_selC) for co-expressing PrdG protein and PrdB protein was constructed.

[0188] 7-2: Co-expression of PrdA, PrdB, PrdH and PrdCG proteins and verification of enhanced D-proline reductase activity - TLC analysis

[0189] The vector expressing PrdA and PrdH proteins (pETDuet_prdH_prdA) and the vector expressing PrdB protein (pCDFDuet_prdB-P selC _selC and pACYCDuet_selA_selB) or a vector expressing PrdA and PrdH proteins (pETDuet_prdH_prdA) and a vector co-expressing PrdB and PrdCG proteins (pCDFDuet_prdG_prdB-P selC _selC and pACYCDuet_selA-prdC_selB) were co-expressed.

[0190] The three expression vectors were transformed into Escherichia coli BL21 (DE3) and cultured in LB medium containing antibiotics (0.1 mg / ml ampicillin, 50 μg / ml spectinomycin and 30 μg / ml chloramphenicol) (37°C, 200 rpm). In order to induce overexpression of the desired protein, the expression of the protein was induced when OD 600 When the value reaches 0.5-0.6, 0.1 mM IPTG is added, and 10 μM sodium selenite is supplied, and then further cultured for 16 hours. The final OD of the obtained E. coli cells is adjusted to 50, followed by centrifugation. After the initial washing, the E. coli cells are diluted with 1 mL of 0.1 M phosphate buffer (pH 8.0).

[0191] Considering that PrdG protein is a membrane protein, 200ul of diluted samples of PrdAHB combination and PrdAHBCG combination were each distributed, and D-proline (final concentration was 10mM) was added, and whole cells, cell lysates, and supernatants obtained by centrifugation under the same OD conditions were reacted in the presence or absence of DTT (final concentration was 25mM) and in the presence or absence of 1% glucose for 6 hours, followed by TLC analysis.

[0192] As a result of the experiment, the PrdAHBCG combination containing the PrdC protein exhibited activity in the presence or absence of DTT ( Fig. 9 , wo, lanes 4 to 6), and in particular, when DTT was added to the supernatant of the cell lysate and allowed to react, the PrdAHBCG combination showed a lower level of activity than the PrdAHB combination ( Fig. 9 , DTT, lane 6).

[0193] These results indicate that a significant portion of the expressed D-proline reductase was removed by centrifugation, and that the expressed D-proline reductase was removed after precipitation by centrifugation due to binding to the PrdG protein, which has membrane protein characteristics. Further, in the DTT-based conversion reaction, both the PrdAHB and PrdAHBCG combinations showed similar activity levels in both whole cells and cell lysates. When 1% glucose was added to increase the supply of NADH without DTT, only the PrdAHBCG combination showed activity ( Fig. 9 , 1% glucose). Based on the experimental results of Example 6, it can be seen that the PrdC protein is related to the utilization of NADH. It can be seen that by binding to the PrdC protein, the PrdG protein induces the formation of a D-proline reductase complex, which easily utilizes intracellular NADH. In other words, when a reducing agent such as DTT is used, electrons may be directly transferred to the D-proline reductase with or without a mediator protein. However, when intracellular NADH is used without external addition of a reducing agent, a mediator protein (PrdC protein) that can help electron transfer is required, and in order to construct an effective electron transfer system, the PrdG protein plays a role in increasing the integration of D-proline reductase, thereby playing a role in improving activity.

[0194] Example 8: Preparation of a strain producing 5-aminovaleric acid from D-proline using the auxiliary protein PrdH

[0195] 8-1: Preparation of strains producing 5-aminovaleric acid

[0196] In order to produce 5-aminovaleric acid from a sugar source by a microorganism, it is necessary to supply D-proline, which is a substrate for D-proline reductase. However, since Escherichia coli does not have a D-proline biosynthetic pathway, a metabolic pathway using D-proline converted by L-proline was designed. In detail, a proline racemase having the ability to form proline isomers must be present at the same time. Therefore, in the present disclosure, experiments were conducted by introducing a proline racemase, which is a known technology (Rudnick et al., Biochemistry, 1975, 14 (20), 4515-4522).

[0197] To this end, in order to insert the prdF gene (amino acid sequence: Q17ZY4, UniProtKB, SEQ ID NO: 17 / nucleotide sequence: CD630_32370, NCBIGeneBank AM180355.1, SEQ ID NO: 18) of the proline racemase protein derived from Peptostreptococcus 630 (Clostridium difficile 630) into the existing D-proline reductase expression system, a ribosome binding site was added between the respective genes for co-expression with the PrdG protein, and then a restriction enzyme sequence of the NcoI / NotI combination was added to both ends for synthesis (prdGF).

[0198] The previously constructed pCDFDuet_prdG_prdB-P was digested with a combination of NcoI / NotI restriction enzymes. selC _selC expression vector and the synthetic prdGF gene were constructed, and each gene fragment was obtained by separation on agarose gel. The expression vector pCDFDuet_prdGF_prdB-P was constructed by T4 ligase enzymatic reaction. selC _selC vector.

[0199] 8-2: Verification of 5-aminovaleric acid production by active D-proline reductase - LC / MS and TLC analysis

[0200] The vectors expressing PrdA and PrdH proteins (pETDuet_prdH_prdA) and PrdBCG (pCDFDuet_prdG_prdB-P selC _selC and pACYCDuet_selA-prdC_selB vectors), as well as a vector expressing PrdA and PrdH proteins (pETDuet_prdH_prdA) and a vector expressing PrdBCGF (pCDFDuet_prdGF_prdB-P selC The two combinations of expression vectors were transformed into Escherichia coli BL21 (DE3) and cultured in LB medium containing antibiotics (0.1 mg / ml ampicillin, 50 μg / ml spectinomycin and 30 μg / ml chloramphenicol) (37°C, 200 rpm). In order to induce overexpression of the desired protein, when OD 600 When the value reached 0.5 to 0.6, 0.1 mM IPTG was added, and 10 μM sodium selenite and 1% glucose (NADH enhancement) were supplied, and then further cultured at 30° C., 200 rpm for 24 hours. The culture medium obtained by centrifugation was subjected to LC / MS and TLC analysis.

[0201] As a result of the experiment, about 67.7 ppm of 5-aminovaleric acid ( Fig.10 , lane 3), while no 5-aminovaleric acid was produced in the absence of proline racemase ( Fig.10 , lanes 1 to 2). In other words, it was confirmed that L-proline was produced from the added sugar source by metabolism in E. coli, then converted into D-proline by proline racemase, and finally, 5-aminovaleric acid was produced by the introduced active D-proline reductase.

[0202] 8-3: Production of 5-aminovaleric acid from D-proline added to the culture medium

[0203] In addition to the process of producing 5-aminovaleric acid from a sugar source by direct fermentation, experiments were also conducted on the conversion of D-proline, which was added externally during the cultivation of a microorganism containing an active D-proline reductase, into 5-aminovaleric acid.

[0204] In detail, an experiment was conducted to examine whether 5-aminovaleric acid can be biosynthesized from D-proline added to the culture medium. To this end, a previously constructed vector expressing PrdA and PrdH proteins (pETDuet_prdH_prdA) and a vector expressing PrdBCG protein (pCDFDuet_prdG_prdB-P selC The three expression vectors were transformed into Escherichia coli BL21 (DE3) and cultured in LB medium containing antibiotics (0.1 mg / ml ampicillin, 50 μg / ml spectinomycin and 30 μg / ml chloramphenicol) (37°C, 200 rpm). In order to induce the overexpression of the desired protein, when OD 600 When the value reached 0.5 to 0.6, 0.1 mM IPTG was added, and 10 μM sodium selenite and 1% glucose were supplied, followed by further culturing at 30°C, 200 rpm for 24 hours in the presence of 5 mM D-proline. The culture medium obtained by centrifugation was subjected to LC / MS analysis.

[0205] The results of the analysis confirmed that 5-aminovaleric acid was not observed in the absence of D-proline, whereas in the presence of 5 mM D-proline, 196.7 ppm (1.68 mM) of 5-aminovaleric acid was produced on average, as confirmed by HPLC (Shimadzu) analysis.

[0206] Example 9: Evaluation of D-proline analog substrates based on D-proline reductase

[0207] In order to further confirm the activity of the constructed active D-proline reductase, conversion reactions were performed on various substrates other than proline. In this example, D-azetidine-2-carboxylic acid (D-Aze), cis-4-hydroxy-D-proline, and trans-4-hydroxy-D-proline, which have a structure similar to D-proline, in which a hydroxyl group (-OH) is added to the ring structure of D-proline, were used as substrates for D-proline reductase.

[0208] To this end, the previously constructed vectors expressing PrdA and PrdH proteins (pETDuet_prdH_prdA) and the vector expressing PrdB protein (pCDFDuet_prdB-P selC The three expression vectors were transformed into E. coli BL21 (DE3) and cultured in LB medium containing antibiotics (0.1 mg / ml ampicillin, 50 μg / ml spectinomycin and 30 μg / ml chloramphenicol) (37°C, 200 rpm). In order to induce the overexpression of the desired protein, when OD 600 When the value reached 0.5 to 0.6, 0.1 mM IPTG was added, and 10 μM sodium selenite was supplied, and then cultured for further 16 hours. The final OD of the obtained E. coli cells was adjusted to 50, followed by centrifugation. After the initial wash, the E. coli cells were diluted with 1 mL of 0.1 M phosphate buffer (pH 8.0). Next, 200 ul of the diluted sample was distributed, and DTT (final concentration of 25 mM) and various substrates (final concentration of 10 mM, Fig.11 A), and allowed to react for 6 hours, followed by TLC analysis. Compared with D-proline, D-azetidine-2-carboxylic acid has a 4-membered ring structure due to the lack of one carbon atom, and when converted by D-proline reductase, γ-aminobutyric acid (GABA) is produced. As a result of the reaction, D-azetidine-2-carboxylic acid showed a relatively low reaction rate compared with D-proline, but GABA production was clearly observed on TLC ( Fig.11 B, lane 6).

[0209] When cis-4-hydroxy-D-proline or trans-4-hydroxy-D-proline is subjected to conversion reaction, 5-amino-4-hydroxyvaleric acid is produced. As a result of the reaction, cis-4-hydroxy-D-proline or trans-4-hydroxy-D-proline shows a lower reaction rate than D-proline, but regardless of the isomeric form of the hydroxyl group, substrate reduction ( Fig.11 C, lanes 5 and 8).

[0210] These results indicate that the expressed active D-proline reductase is capable of converting other substrates with ring structures of different sizes and substrate analogs with additional modifications as well as the known D-proline.

[0211] Based on the above description, it will be understood by those skilled in the art that the present disclosure can be implemented in different specific forms without changing its technical spirit or basic features. Therefore, it should be understood that the above-mentioned embodiments are not restrictive in all aspects, but illustrative. The scope of the present disclosure is limited by the attached claims rather than by the previous description thereof, and therefore, all changes and modifications falling within the limits of the claims or the equivalents of such limits are therefore intended to be covered by the attached claims.

[0212] International Forms

[0213] Original deposit receipt certificate

[0214] Issued under clause 7.1

[0215] To: CJ CheilJedang Co., Ltd.

[0216] CJ CheilJedang Center

[0217] 330, DONGHO-RO, JUNG-GU, Seoul 100-400

[0218] Republic of Korea

[0219]

[0220] Certify that the above translation is correct with the original text

[0221] July 12, 2017

[0222] Patent Attorney Son Minyin <110> CJ CheilJedang Co., Ltd. <120> Microorganism expressing active D-proline reductase and method for producing active D-proline reductase <130> OPA18191 <150> KR 10-2017-0088632 <151> 2017-07-12 <160> 26 <170> KoPatentIn 3.0 <210> 1 <211> 94 <212> PRT <213> unknown <220> <223> PrdH <400> 1 Methionine, Aspartic acid, Arginine, Leucine, Lysine, Tyrosine, Isoleucine, Serine, Serine, Glutamic acid, Threonine, Phenylalanine, Tyrosine, Glutamic acid, Glycine, Isoleucine 1 5 10 15 Isoleucine, Valine, Aspartic acid, Isoleucine, Lysine, Glycine, Glycine, Glycine, Valine, Threonine, Isoleucine, Aspartic acid, Leucine, Lysine, Glycine, Arginine 20 25 30 Leucine, Glycine, Glutamine, Phenylalanine, Lysine, Isoleucine, Proline, Asparagine, Arginine, Methionine, Leucine, Isoleucine, Threonine, Aspartic acid, Tyrosine, Glutamic acid 35 40 45 Leucine, Lysine, Isoleucine, Glycine, Glutamine, Glutamic acid, Valine, Glycine, Phenylalanine, Methionine, Leucine, Serine, Tyrosine, Proline, Glutamic acid, Valine 50 55 60 Leucine, Serine, Proline, Glutamic acid, Proline, Asparagine, Glutamine, Glutamic acid, Tyrosine, Valine, Glutamic acid, Asparagine, Isoleucine, Arginine, Arginine, Glutamic acid 65 70 75 80 Lysine, Glutamic acid, Lysine, Glutamine, Alanine, Glutamic acid, Methionine, Glutamine, Serine, Lysine, Glutamine, Glutamic acid, Glutamic acid, Lysine 85 90 <210> 2 <211> 285 <212> DNA <213> Unknown <220> <223> PrdH <400> 2 atggataggt taaaatatat ctcatcagag actttttatg aaggtattat agttgacatc 60 aaaggcggtg gagtgactat agacctaaaa ggtagacttg gacaatttaa aatacctaat 120 agaatgctta taactgacta cgaacttaag ataggtcaag aagttggatt catgctaagc 180 tatcctgagg tattaagtcc agagcctaat caagagtatg tagaaaatat taggagagaa 240 aaagaaaaac aagcagaaat gcaatcaaaa caagaagaaa aataa 285 <210> 3 <211> 626 <212> PRT <213> Unknown <220> <223> PrdA <400> 3 Met Ser Ile Thr Leu Glu Thr Ala Gln Ala His Ala Asn Asp Pro Ala 1 5 10 15 Val Cys Cys Cys Arg Phe Glu Ala Gly Thr Ile Ile Ala Pro Glu Asn 20 25 30 Leu Glu Asp Pro Ala Ile Phe Ala Asp Leu Glu Asp Ser Gly Leu Leu 35 40 45 Thr Ile Pro Glu Asn Gly Leu Thr Ile Gly Gln Val Leu Gly Ala Lys 50 55 60 Leu Lys Glu Thr Leu Asp Ala Leu Ser Pro Met Thr Thr Asp Asn Val 65 70 75 80 Glu Gly Tyr Lys Ala Gly Glu Ala Lys Glu Glu Val Val Glu Glu Thr 85 90 95 Val Glu Glu Ala Ala Pro Val Ser Glu Ala Ala Val Val Pro Val Ser 100 105 110 Thr Gly Val Ala Gly Glu Thr Val Lys Ile His Ile Gly Glu Gly Lys 115 120 125 Asn Ile Ser Leu Glu Ile Pro Leu Ser Val Ala Gly Gln Ala Gly Val 130 135 140 Ala Ala Pro Val Ala Asn Val Ala Ala Pro Val Ala Ser Ala Ala Ala 145 150 155 160 Glu Val Ala Pro Lys Val Glu Glu Lys Lys Leu Leu Arg Ser Leu Thr 165 170 175 Lys Lys His Phe Lys Ile Asp Lys Val Glu Phe Ala Asp Glu Thr Lys 180 185 190 Ile Glu Gly Thr Thr Leu Tyr Ile Arg Asn Ala Glu Glu Ile Cys Lys 195 200 205 Glu Ala Asn Glu Thr Gln Glu Leu Val Val Asp Met Lys Leu Glu Ile 210 215 220 Ile Thr Pro Asp Lys Tyr Glu Thr Tyr Ser Glu Ala Val Leu Asp Ile 225 230 235 240 Gln Pro Ile Ala Thr Lys Glu Glu Gly Glu Leu Gly Ser Gly Ile Thr 245 250 255 Arg Val Ile Asp Gly Ala Val Met Val Leu Thr Gly Thr Asp Glu Asp 260 265 270 Gly Val Gln Ile Gly Glu Phe Gly Ser Ser Glu Gly Glu Leu Asn Thr 275 280 285 Thr Ile Met Trp Gly Arg Pro Gly Ala Ala Asp Lys Gly Glu Ile Phe 290 295 300 Ile Lys Gly Gln Val Thr Ile Lys Ala Gly Thr Asn Met Glu Arg Pro 305 310 315 320 Gly Pro Leu Ala Ala His Arg Ala Phe Asp Tyr Val Thr Gln Glu Ile 325 330 335 Arg Glu Ala Leu Lys Lys Val Asp Asn Ser Leu Val Val Asp Glu Glu 340 345 350 Val Ile Glu Gln Tyr Arg Arg Glu Gly Lys Lys Lys Val Val Val Ile 355 360 365 Lys Glu Ile Met Gly Gln Gly Ala Met His Asp Asn Leu Ile Leu Pro 370 375 380 Val Glu Pro Val Gly Thr Leu Gly Ala Gln Pro Asn Val Asp Leu Gly 385 390 395 400 Asn Met Pro Val Val Leu Ser Pro Leu Glu Val Leu Asp Gly Gly Ile 405 410 415 His Ala Leu Thr Cys Ile Gly Pro Ala Ser Lys Glu Met Ser Arg His 420 425 430 Tyr Trp Arg Glu Pro Leu Val Ile Arg Ala Met Glu Asp Glu Glu Ile 435 440 445 Asp Leu Val Gly Val Val Phe Val Gly Ser Pro Gln Val Asn Ala Glu 450 455 460 Lys Phe Tyr Val Ser Lys Arg Leu Gly Met Leu Val Glu Ala Met Glu 465 470 475 480 Val Asp Gly Ala Val Val Thr Thr Glu Gly Phe Gly Asn Asn His Ile 485 490 495 Asp Phe Ala Ser His Ile Glu Gln Ile Gly Met Arg Gly Ile Pro Val 500 505 510 Val Gly Val Ser Phe Ser Ala Val Gln Gly Ala Leu Val Val Gly Asn 515 520 525 Lys Tyr Met Thr His Met Val Asp Asn Asn Lys Ser Lys Gln Gly Ile 530 535 540 Glu Asn Glu Ile Leu Ser Asn Asn Thr Leu Ala Pro Glu Asp Ala Val 545 550 555 560 Arg Ile Met Ala Met Leu Lys Asn Ala Ile Glu Gly Val Glu Val Lys 565 570 575 Ala Pro Glu Arg Lys Trp Asn Pro Asn Val Lys Leu Asn Asn Ile Glu 580 585 590 Ala Ile Glu Lys Val Thr Gly Glu Lys Ile Val Leu Glu Glu Asn Glu 595 600 605 Gln Ser Leu Pro Met Ser Lys Lys Arg Arg Glu Ile Tyr Glu Lys Asp 610 615 620 Glu Asn 625 <210> 4 <211> 1881 <212> DNA <213> Unknown <220> <223> PrdA <400> 4 atgtcaataa ctttagaaac agctcaagcc catgcaaatg acccagcagt ttgttgttgt 60 agatttgaag cgggaacaat tatagcgcca gaaaacttag aagatccagc aatatttgca 120 gacttagagg attctggatt attaacaata ccagaaaatg gattaactat aggtcaagta 180 ctaggagcta agttaaaaga aactttagat gcactttctc caatgactac agataacgta 240 gaaggataca aagcaggaga ggctaaagaa gaagtagtag aagaaacagt agaagaagca 300 gctccagtat cagaagcagc agtagttcca gtaagcacag gagttgcagg tgaaacagtt 360 aaaatacaca taggtgaagg taagaacata agcttagaga tacctttatc agtagctggt 420 caagcaggag tgctgctcc agtagcaaac gttgctgctc cagtggcaag tgcagcagca 480 gaagtagctc caaagttga agaaaagaa cttttaagaa gcttaacta aaaacacttt 540 aaatagata aagttgaatt tgctgatgaa actaaaatag aaggaactac ttatacatc 600 agaaacgcag aagaaatatg taagaagct aatgaactc aagagttagt tgtagatatg 660 aagttagaaa taatactcc tgataataat gaacttaca gtgaagctgt attagatata 720 stormcg ctactaaga agaggcgaa ttaggttcag gtataactag agttatagat 780 ggagctgtaa tgtattaac tgtacagat gaagatggag ttcaatagg tgaatttggt 840 tcttcagaag gtgagttaaa tactactata atgtgggta gaccaggtgc tgctgacaaa 900 ggtgaaatat tcatcaagg tcaagtaca aaaagcag gaactacat ggaaagacca 960 ggacctttag ctgctcaccg tgcattgac tatgtactc aagaataag agaagcatta 1020 aagaaagttg acaactcttt agtagttgat gagagta tagagata spring 1080 ggtaaaaga aagttgttgt tataaaaga atatgggac aaggtgcaat gcatgataac 1140 ctaatattac cagttgagcc agttggtaca ttaggagctc aaccaaacgt tgacttagga 1200 aacatgccag ttgtattatc tccacttgaa gtattagatg gtggtatcca tgcattaact 1260 tgtataggac ctgcatcaa agaatgtca agacattact ggagagagcc attagtaata 1320 agagctatgg agacgaga atagattta gtaggtgttg tattgttgg ttctccacaa 1380 gtaaatgctg agaattcta tgtatctag agattagta tgttagttga agctatggaa 1440 gttgatggag ctgtagtaac tactgaggt tcggaaca accatataga ttcgcatct 1500 cacatagagc aaataggtat gagaggtata ccagtagttg gtgtaagtttt ctcagctgtt 1560 caagtgctc tagttgttgg taaatac atgactcaca tggtagacaa caatagtct 1620 aagcaggta taggaatga atattatct aaaacactt tagctccaga agatgctgtt 1680 agaataatgg ctagcttaa aaatgctata gaggtgtag agttaaagc tcctgaaaga 1740 aaatggaatc aaatgttaa atataac atagagcta tagaaaagt tacaggaa 1800 aaatagtat taggagaa tgagcaatct ctaccaatga gtaagagag aagagaata 1860 tacgaaaaag acgaaaacta a 1881 <210> 5 <211> 240 <212> PRT <213> Unknown <220> <223> PrdB <400> 5 Met Ser Leu Thr Thr Val Gln Gly Leu Gln Ser Glu Ile Phe Val Pro 1 5 10 15 Ile Thr Pro Pro Pro Val Trp Thr Pro Val Thr Lys Glu Leu Lys Asp 20 25 30 Met Thr Ile Ala Leu Ala Thr Ala Ala Gly Val His Leu Lys Ser Asp 35 40 45 Lys Arg Phe Asn Leu Ala Gly Asp Thr Thr Phe Arg Ala Ile Pro Asn 50 55 60 Thr Ala Thr Val Asp Glu Met Met Val Ser His Gly Gly Tyr Asp Asn 65 70 75 80 Gly Asp Val Asn Lys Asp Ile Asn Cys Met Phe Pro Ile Asp Arg Leu 85 90 95 His Glu Leu Ala Ala Glu Gly Phe Ile Lys Gly Val Ala Pro Met His 100 105 110 Tyr Ala Phe Met Gly Gly Gly Gly Asn Gln His Val Phe Thr Glu Glu 115 120 125 Thr Gly Pro Ala Ile Ala Ala Lys Leu Lys Glu Glu Gly Val Asp Gly 130 135 140 Val Val Met Thr Ala Gly Gly Thr Cys His Arg Thr Ala Val Ile Val 145 150 155 160 Gln Arg Ala Ile Glu Glu Ala Gly Ile Pro Thr Ile Ile Ile Ala Ala 165 170 175 Leu Pro Pro Val Val Arg Gln Asn Gly Thr Pro Arg Ala Val Ala Pro 180 185 190 Leu Val Pro Met Gly Ala Asn Ala Gly Glu Pro His Asn Ile Glu Met 195 200 205 Gln Thr His Ile Leu Arg Asp Thr Leu Glu Gln Leu Val Ala Ile Pro 210 215 220 Ser Ala Gly Lys Ile Val Pro Leu Pro Tyr Glu Tyr Lys Ala His Val 225 230 235 240 <210> 6 <211> 726 <212> DNA <213> Unknown <220> <223> PrdB <400> 6 atgagcctta caacagtaca aggacttcaa tctgaaatat tcgttccaat aacacctcct 60 ccagtttgga ctcctgtaac taaagaatta aaagatatga ctatagcttt agctacagca 120 ccagtttgga ctcctgtaac taaagaatta aaagatatga ctatagcttt agctacagca 120 gctggtgttc atttaaaatc tgacaagaga tttaatctag caggagatac tacatttaga 180 gctggtgttc atttaaaatc tgacaagaga tttaatctag caggagatac tacatttaga 180 gctataccta atacagctac agttgatgaa atgatggtat cacatggtgg atatgacaat 240 gctataccta atacagctac agttgatgaa atgatggtat cacatggtgg atatgacaat 240 ggagatgtaa acaaagatat aaactgtatg ttccctatag atagattaca tgaattagct 300 ggagatgtaa acaaagatat aaactgtatg ttccctatag atagattaca tgaattagct 300 gcagaaggat ttatcaaagg agtagctcct atgcactatg cattcatggg tggtggagga 360 gcagaaggat ttatcaaagg agtagctcct atgcactatg cattcatggg tggtggagga 360 aaccaacatg tcttcactga agaaactggt cctgctatcg ctgctaaact taaggaagag 420 aaccaacatg tcttcactga agaaactggt cctgctatcg ctgctaaact taaggaagag 420 ggagtagacg gtgtagttat gacagctggc tgaggtactt gccatagaac tgccgtgatc 480 ggagtagacg gtgtagttat gacagctggc tgaggtactt gccatagaac tgccgtgatc 480 gtgcagagag caatagagga agctggaata cctacaataa taatagcagc tcttcctcca 540 gtgcagagag caatagagga agctggaata cctacaataa taatagcagc tcttcctcca 540 gtagttagac aaaacggaac tcctagagca gttgctccat tagttccaat gggtgctaat 600 gtagttagac aaaacggaac tcctagagca gttgctccat tagttccaat gggtgctaat 600 gctggtgaac cacataatat agaaatgcaa acacatatat taagagatac attagagcaa 660 gctggtgaac cacataatat agaaatgcaa acacatatat taagagatac attagagcaa 660 ttagttgcaa taccatctgc tggtaagata gttccattac catacgaata taaagctcac 720 ttagttgcaa taccatctgc tggtaagata gttccattac catacgaata taaagctcac 720 gtttaa 726 gtttaa 726 <210> 7 <210> 7 <211> 252 <211> 252 <212> PRT <212> PRT <213> 未知 <213> Unknown <220> <223> PrdD <400> 7 Met Glu Glu Lys Ile Met Arg Arg Leu Val Ile Lys Pro Phe His Met 1 5 10 15 Asn Glu Val Asn Phe Gly Ser Lys Thr Ser Ile Lys Lys Asp Val Leu 20 25 30 Thr Ile Asp Leu Ser Ser Ile Asp Glu Ile Lys Glu Arg Glu Glu Leu 35 40 45 Ile Thr Asp Ile Lys Val Asp Ile Ile Lys Pro Gly Asp Tyr Asp Arg 50 55 60 Glu Ile Asn Thr Ile Met Asp Ile Ile Pro Ile Ser Thr Lys Val Leu 65 70 75 80 Gly Arg Leu Gly Glu Gly Ile Thr His Thr Leu Thr Gly Val Tyr Val 85 90 95 Met Leu Thr Gly Ala Asp Glu Asp Gly Asn Gln Met His Glu Phe Gly 100 105 110 Ser Ser Glu Gly Ile Leu Lys Asp Gln Met Val Phe Gly Arg Tyr Gly 115 120 125 Thr Pro Ser Val Glu Asp Tyr Ile Ile His Val Asp Val Thr Leu Lys 130 135 140 Gly Gly Leu Pro Phe Glu Arg Thr Leu Pro Leu Ala Ala Phe Arg Ala 145 150 155 160 Cys Asp Asp Phe Ile Gln Glu Ile Arg Ala Ser Leu Lys Met Glu Asp 165 170 175 Gly Arg Asn Ala Thr Gln Val Arg Glu Tyr Phe Asp Lys Ile Arg Pro 180 185 190 Asn Ala Lys Lys Val Val Ile Val Lys Gln Ile Ala Gly Gln Gly Ala 195 200 205 Met Tyr Asp Asn Gln Leu Phe Ser Lys Glu Pro Ser Gly Phe Glu Gly 210 215 220 Gly Thr Ser Ile Ile Asp Met Gly Asn Val Pro Met Ile Ile Ser Pro 225 230 235 240 Asn Glu Tyr Arg Asp Gly Ala Leu Arg Ala Met Thr 245 250 <210> 8 <211> 759 <212> DNA <213> Unknown <220> <223> PrdD <400> 8 atggaagaaa aaataatgag aagacttgtt ataaaaccgt ttcatatgaa tgaagttaat 60 ttcggttcaa aaacttctat aaagaaagat gtacttacaa tagatttatc aagtatagat 120 gaaataaaag aaagagaaga gttaataaca gacataaaag tagacattat aaaacctgga 180 gattatgaca gagaaattaa tactattatg gacattatac caatatcaac aaaagtttta 240 ggcagactgg gagagggtat tacacatact ttaacgggtg tatatgtaat gttaactggt 300 gcagatgaag atggaaatca aatgcatgaa tttggttctt cagaaggaat tttgaaagac 360 caaatggtat ttgggagata tggaactcca tcagttgaag attatataat ccatgtagat 420 gtaactttaa agggaggttt accttttgaa agaacacttc cacttgcagc attcagagca 480 tgtgatgatt ttatacaaga aataagagca tctttgaaaa tggaagacgg aagaaatgct 540 actcaagttc gtgaatattt tgacaaaatt cgaccaaatg caaaaaaggt tgtcatagta 600 aaacaaatag caggtcaagg tgctatgtat gacaatcagt tattctcaaa ggaacctagt 660 ggatttgaag gaggaacatc aattatagat atgggaaatg tacctatgat tatatctcct 720 aatgaataca gagatggtgc ccttagagct atgacttaa 759 <210> 9 <211> 155 <212> PRT <213> Unknown <220> <223> PrdE <400> 9 Met Gly Ile Gly Pro Ser Thr Lys Glu Thr Ser Leu His His Phe Arg 1 5 10 15 Asp Pro Leu Leu Asp Ile Val Glu Ser Asp Lys Asp Val Asp Leu Leu 20 25 30 Gly Val Ile Val Val Gly Thr Pro Asp Gly Asn Glu Asn Lys Thr Phe 35 40 45 Val Gly Gln Arg Thr Ala Ala Trp Leu Glu Ala Met Arg Val Asp Gly 50 55 60 Ala Ile Val Ser Ser Asp Gly Trp Gly Asn Ser His Val Asp Tyr Ala 65 70 75 80 Asn Thr Phe Glu Glu Ile Gly Lys Arg Asp Ile Pro Val Val Gly Val 85 90 95 Thr Phe Asn Gly Thr Gln Ala Lys Phe Val Val Ser Asn Gln Tyr Met 100 105 110 Asp Thr Ile Val Asp Met Asn Lys Ser Lys Glu Gly Ile Glu Thr Glu 115 120 125 Val Val Gly Glu Asn Asn Thr Asn Glu Ile Asp Ala Lys Lys Ala Leu 130 135 140 Ala Phe Leu Lys Leu Lys Met Arg Lys His Gly 145 150 155 <210> 10 <211> 468 <212> DNA <213> unknown <220> <223> PrdE <400> 10 atgggaatag gaccttcaac aaaagaaaca tctcttcatc actttagaga cccactttta 60 gacatagttg aaagtgataa ggatgtagat ttacttggag taatagtagt aggaactcca 120 gatggaaatg aaaataaaac ctttgtggga caaagaacgg ccgcttggct ggaagccatg 180 agagtagatg gagctatagt ttcatcagat ggttggggaa actcacatgt tgactacgct 240 aacacatttg aggaaatagg aaaaagagat atacctgtag ttggagttac atttaatggg 300 actcaagcta agtttgttgt aagcaatcaa tatatggata ccatagttga tatgaacaaa 360 tcaaaagaag gtattgagac agaagtagtt ggagaaaaca acacaaatga aatagatgct 420 aaaaaagctt tggcattttt aaaacttaaa atgagaaaac atggataa 468 <210> 11 <211> 160 <212> PRT <213> unknown <220> <223> PrdE2 <400> 11 Met Ser Phe Val Gly Ile Ser Thr Ser Met Lys Asn Thr Ser Leu His 1 5 10 15 Ile Phe Arg Asp Pro Leu Leu Asp Leu Ile Asp Asn Asp Ser Asp Ile 20 25 30 Asp Leu Leu Gly Val Val Val Val Gly Thr Ser Glu His Asn Glu Trp 35 40 45 Lys Thr Phe Leu Ala Thr Arg Leu Gly Arg Trp Ile Glu Ser Leu Arg 50 55 60 Pro Asp Gly Val Ile Ile Thr Leu Asp Met Ala Gly Asn Gln His Ile 65 70 75 80 Asp Phe Thr Asn Ala Ile Ala Glu Phe Val Lys Ser Asp Ile Pro Thr 85 90 95 Val Gly Leu Thr Ile Met Gly Ala Asp Gly Leu Val Ile Thr Asn Pro 100 105 110 Tyr Leu Asp Lys Ala Thr Ile Ile Asp Tyr Lys Lys Thr Thr Gly Tyr 115 120 125 Ile Glu Thr Glu Val Val Gly Asp Asn His Met Asp Glu Val Asp Val 130 135 140 Lys Lys Ala Leu Ala Phe Leu Lys Leu Lys Met Arg Lys Asp Ala Lys 145 150 155 160 <210> 12 <211> 483 <212> DNA <213> Unknown <220> <223> PrdE2 <400> 12 atgagttttg tgggaatttc tacatcaatg aaaaacacat cacttcatat atttagagac 60 ccgttactag atttgataga taatgattct gacatagact tgttaggagt ggttgtagtt 120 gggacatcag agcacaatga atggaaaaca tttttagcaa ctagacttgg aagatggatt 180 gaatcattgc gacctgatgg agtgattata actttagata tggcaggaaa ccagcacatt 240 gattttacaa atgctatagc agagtttgta aaatcagata tacctacagt aggtcttact 300 attatgggag cagatggatt agtaattacc aatccatatt tggataaagc taccataatt 360 gattataaaa agacaacagg ctacatagaa acagaagtag ttggagacaa tcacatggac 420 gaagttgatg ttaaaaaagc attggctttc ctaaaattaa aaatgcgtaa agacgcaaaa 480 taa 483 <210> 13 <211> 437 <212> PRT <213> Unknown <220> <223> PrdC <400> 13 Met Asn Lys Leu Tyr Ser Ile Leu Leu Lys Gln His Val Gly Gly Pro 1 5 10 15 Asp Lys Pro Val Val Ser Val Gly Asp Val Val Lys Lys Gly Thr Leu 20 25 30 Ile Ala Glu Pro Thr Gly Leu Gly Ala Asn Ile Tyr Ala Ser Val Ser 35 40 45 Gly Lys Ile Ser Glu Ile Asn Asp Gln Ala Ile Val Ile Glu Ala Asp 50 55 60 Glu Val Gln Glu Asp Thr Phe Glu Pro Leu Lys Gly Glu Gly Ile Leu 65 70 75 80 Asp Leu Ile Lys Glu Ala Gly Val Val Gly Met Gly Gly Ala Gly Phe 85 90 95 Pro Thr His Val Lys Leu Asn Ile Asp Leu Asn Gly Gly Thr Ile Leu 100 105 110 Ala Asn Ala Ala Glu Cys Glu Pro Leu Leu Ala His Asn Ile Lys Glu 115 120 125 Ile Glu Glu Arg Pro Glu Ile Val Tyr Gln Gly Ile Lys Tyr Ala Met 130 135 140 Glu Val Thr Asn Ala Gly Lys Gly Met Leu Ala Ile Lys Ser Lys His 145 150 155 160 Pro Lys Ala Ile Glu Ala Phe Lys Lys Val Ile Lys Pro Gly Asp Asn 165 170 175 Ile Glu Val Ala Glu Leu Val Asp Met Tyr Pro Met Gly Glu Glu Arg 180 185 190 Ala Ile Val Arg Asp Val Leu Gly Lys Leu Leu Glu Pro Thr Gln Leu 195 200 205 Pro Ser Glu Ala Asn Ala Val Val Ile Asn Val Glu Thr Leu Thr Arg 210 215 220 Ile Val Glu Ala Val Glu Gln Lys Arg Pro Val Ile Ser Lys Asn Ile 225 230 235 240 Thr Val Val Gly Gln Leu Asn Ser Gly Lys Glu Ser Ile Val Phe Glu 245 250 255 Asp Val Pro Ile Gly Thr Thr Val Gly Glu Leu Ile Glu Arg Ala Gly 260 265 270 Gly Ile Lys Gly Glu Tyr Gly Glu Ile Ile Leu Gly Gly Pro Phe Thr 275 280 285 Gly Lys Ala Thr Thr Leu Asp Ala Pro Ile Thr Lys Thr Ser Gly Gly 290 295 300 Ile Ile Val Thr Met Pro Phe Val Asn Glu Lys Arg Lys Met Gly Leu 305 310 315 320 Leu Val Cys Ala Cys Gly Pro Asn Glu Glu Arg Met Arg Asp Ile Ala 325 330 335 Thr Lys Met Gly Val Thr Asp Ile Val Ser Val Gln Lys Cys Lys Gln 340 345 350 Ala Gln Glu Ile Lys Gly Ala Leu Lys Cys Glu Asn Pro Gly His Cys 355 360 365 Pro Gly Gln Ala Gln Lys Cys Ile Glu Phe Lys Lys Ala Gly Ala Glu 370 375 380 Val Ile Leu Ile Gly Asn Cys Thr Asp Cys Ser Asn Thr Val Met Gly 385 390 395 400 Ser Ala Pro Lys Leu Lys Leu Gly Val Tyr His Ile Thr Asp His Val 405 410 415 Met Arg Thr Val Asn His Pro Leu Ile Arg Arg Ile Lys Gly Asp Val 420 425 430 Arg Leu Lys Ile Lys 435 <210> 14 <211> 1314 <212> DNA <213> Unknown <220> <223> PrdC <400> 14 ttgaacaaac tatattctat tttattaaaa caacacgttg gtggtccaga taagccagta 60 gtaagtgttg gagatgtagt aaaaaagga actctaatcg cagaaccac tggattaggg 120 gcaatatttt atgccagtgt tagtggaaaa atagtgaaa taaatgacca agcgagta 180 attgaagctg atgaagtaca agaagatact ttgaaccat taaaggaga aggtatactt 240 gacttatta agaagctgg agtagtagga atgggtggag caggattccc tactcatgta 300 aaattaaca tagattaa tggtgaaca atattagca atgcagctga atgtgaacct 360 ttattagctc attaataa agaatagaa gaagaccag aaatagtttta tcaggtata 420 aaatatgcta tggagttac taatgctgga aaagtagc tagcataaa agtaagcat 480 ccaaaagca taagcttt aaaaaagccag gagacacat agaagttgca 540 gaactagttg atatgtaccc aatgggagaa gagagagca tagtagaga cgttctagga 600 aaattacttg agccaactca attackca gaggctaatg cagtagtaat aaacgtagaa 660 acactaacta cagttataga ggctgttgag caaaaagac cagttatatc taaaatata 720 actgtagttg gtcaattaaa cagtggaaaa gatctatag tgtttgaaga tgtgccaatt 780 ggaacaactg tcggagaatt aattgaaaga gctggtggaa taaaaggtga atatggtgaa 840 ataatcctag gaggaccttt cactggtaaa gctactactt tagatgctcc aataactaaa 900 actagtggtg gtataatagt tactatgcca tttgttaatg aaaagagaaa aatgggtctt 960 ttagtttgtg catgtggacc taatgaagaa agaatgagag atatagcaac taaaatggga 1020 gttactgata tagtatcagt tcaaaaatgt aaacaagctc aagaaattaa aggtgcatta 1080 aaatgtgaaa atccaggaca ctgtccagga caagctcaaa aatgtattga atttaagaaa 1140 gctggagcag aagttatatt aataggaaac tgtactgact gtagtaacac agtaatgggt 1200 tctgcaccaa aattaaaatt aggtgtatat catattactg accatgtaat gagaacagtt 1260 aatcacccat taataagaag aataaaaggt gacgtaagat taaaaataaa ataa 1314 <210> 15 <211> 293 <212> PRT <213> Unknown <220> <223> PrdG <400> 15 Met Val Ala Ile Leu Lys Ala Leu Tyr Val Val Phe Ala Ala Ile Phe 1 5 10 15 Ala Val Val Phe Gly Lys Asp Val Ala Lys Ala Asn Lys Glu Gly Lys 20 25 30 Leu Glu Glu Gln Ser Thr Pro Lys Val Ala Val Thr Gly Phe Ile Thr 35 40 45 Asp Phe Phe Asp Thr Leu Gly Ile Gly Ser Phe Ala Pro Thr Ile Ala 50 55 60 Met Ser Lys Ala Leu Lys Leu Asn Ile Pro Asp Lys Lys Met Pro Gly 65 70 75 80 Thr Leu Asn Val Ala His Thr Ile Pro Val Val Thr Glu Ala Phe Ile 85 90 95 Phe Thr Ser Ile Ile Pro Val Asp Gly Val Thr Leu Val Ser Met Val 100 105 110 Val Ala Ala Ala Val Gly Ser Tyr Ile Gly Ala Gly Ile Ile Ala Lys 115 120 125 Met Asp Glu Arg Lys Ile Gln Leu Val Met Gly Val Thr Leu Ala Leu 130 135 140 Thr Ala Ile Leu Met Leu Leu Gly His Pro Trp Ile Asn Val Leu Pro 145 150 155 160 Gly Gly Gly Asn Glu Leu Gly Leu Thr Gly Val Lys Leu Val Ile Gly 165 170 175 Val Ile Gly Asn Phe Ile Leu Gly Ala Leu Met Thr Ala Gly Ile Gly 180 185 190 Leu Tyr Ala Pro Gly Met Ala Met Val Tyr Phe Leu Gly Met Ser Ala 195 200 205 Lys Val Ala Phe Pro Ile Val Met Gly Ser Cys Ala Leu Leu Met Pro 210 215 220 Val Ala Ser Met Lys Phe Ile Lys Glu Asp Ala Tyr Thr Lys Lys Ala 225 230 235 240 Ser Val Ile Ile Ala Ile Cys Gly Leu Ile Gly Val Phe Val Ala Ala 245 250 255 Tyr Ile Val Lys Thr Leu Pro Met Asp Ile Leu Lys Ala Leu Val Ile 260 265 270 Val Val Ile Ala Tyr Thr Ser Ala Thr Met Ile Met Ala Ala Asn Lys 275 280 285 Asn Lys Lys Thr Ala 290 <210> 16 <211> 882 <212> DNA <213> Unknown <220> <223> PrdG <400> 16 atggtagcaa tcttaaaggc attatatgta gtattcgcag caatctttgc agttgtgttt 60 ggtaagacg tagctaagc aaaaaagag gggaaaaaag tactccaaaa 120 gttgctgtaa caggatttat aacagacttc ttgatacat taggatagg gtcatttgct 180 ccaacaatag caatgtcaa ggctttaaag ttaatatac cagataaaa atgcctggt 240 acattaaacg tagcacatac tattccagtt gttacagaag cattcatatt tacatcaatc 300 ataccagttg atggtgttac tttagtatct atggttgtgg cagcagcagt tggttcatat 360 ataggtgcag gatataatagc taagatggac gagaaaaa tacaacttgt tatggtgta 420 actttagcat taacagcaat attaatgtta ttaggtcatc cttggattaa cgtattacca 480 ggtggaggaa atgaattagg tcttactggt gttaaattag tataggtgt atgattaac 540 tttatactg gagctttaat jagagctggt atgtctat atgctccagg tatggcaatg 600 gtttatttct taggaatgtc tgcaaagtt gcattcccaa tagttatgg ttctgtgca 660 ttattaatgc cagttgcaag tatgaaattc aaaagaag atgcatatac taaaaaagca 720 tcagttataa tagctatatg tggtttaata ggagttttcg tagctgcata tatagtaaaa 780 actctaccaa tggatatatt aaaagcatta gtaatagtag ttatagctta tacttctgct 840 acaatgataa tggctgcaaa taaaaacaaa aagactgctt ag 882 <210> 17 <211> 335 <212> PRT <213> Unknown <220> <223> PrdF <400> 17 Met Lys Phe Ser Arg Ser Ile Gln Ala Ile Asp Ser His Thr Ala Gly 1 5 10 15 Glu Ala Thr Arg Ile Val Val Gly Gly Ile Pro Asn Ile Lys Gly Asn 20 25 30 Ser Met Pro Glu Lys Lys Glu Tyr Leu Glu Glu Asn Leu Asp Tyr Leu 35 40 45 Arg Thr Ala Ile Met Leu Glu Pro Arg Gly His Asn Asp Met Phe Gly 50 55 60 Ser Val Met Thr Gln Pro Cys Cys Pro Asp Ala Asp Phe Gly Ile Ile 65 70 75 80 Phe Met Asp Gly Gly Gly Tyr Leu Asn Met Cys Gly His Gly Thr Ile 85 90 95 Gly Ala Met Thr Ala Ala Ile Glu Thr Gly Val Val Pro Ala Val Glu 100 105 110 Pro Val Thr His Val Val Met Glu Ala Pro Ala Gly Ile Ile Arg Gly 115 120 125 Asp Val Thr Val Val Asp Gly Lys Ala Lys Glu Val Ser Phe Leu Asn 130 135 140 Val Pro Ala Phe Leu Tyr Lys Glu Gly Val Glu Val Asp Leu Pro Gly 145 150 155 160 Val Gly Thr Val Lys Phe Asp Ile Ser Phe Gly Gly Ser Phe Phe Ala 165 170 175 Ile Ile His Ala Ser Gln Leu Gly Leu Lys Ile Glu Pro Gln Asn Ala 180 185 190 Gly Lys Leu Thr Glu Leu Ala Met Lys Leu Arg Asp Ile Ile Asn Glu 195 200 205 Lys Ile Glu Ile Gln His Pro Thr Leu Ala His Ile Lys Thr Val Asp 210 215 220 Leu Val Glu Ile Tyr Asp Glu Pro Thr His Pro Glu Ala Thr Tyr Lys 225 230 235 240 Asn Val Val Ile Phe Gly Gln Gly Gln Val Asp Arg Ser Pro Cys Gly 245 250 255 Thr Gly Thr Ser Ala Lys Leu Ala Thr Leu His Ala Lys Gly Glu Leu 260 265 270 Lys Val Gly Glu Lys Phe Val Tyr Glu Ser Ile Leu Gly Thr Leu Phe 275 280 285 Lys Gly Glu Ile Val Glu Glu Thr Lys Val Ala Asp Phe Asn Ala Val 290 295 300 Val Pro Lys Ile Thr Gly Ser Ala Tyr Ile Thr Gly Phe Asn His Phe 305 310 315 320 Val Ile Asp Glu Glu Asp Pro Leu Lys His Gly Phe Ile Leu Lys 325 330 335 <210> 18 <211> 1008 <212> DNA <213> Unknown <220> <223> PrdF <400> 18 atgaaattta gcagaagtat acaagctata gactctcata cagcaggtga agcaactaga 60 atagttgtag gtggaatacc taacataaaa ggaaattcta tgcctgagaa aaaagaatat 120 ttagaggaaa atctagatta tttaagaact gctataatgt tagagccaag aggacataat 180 gatatgtttg gttctgtaat gactcaacct tgttgcccag atgctgactt tggaataatc 240 ttcatggatg gtggcggata ccttaacatg tgtggccatg gtacaatagg agctatgaca 300 gcagctatag aaacaggtgt agttccagca gtagagcctg taactcatgt agttatggaa 360 gctccagcag gaataataag aggagacgtt acagttgtag atggaaaagc taaagaagta 420 tcattcttaa acgtaccagc tttcttatat aaagaaggtg ttgaagttga cttaccaggt 480 gttggaactg ttaaatttga catatcattt ggtggaagct tctttgctat aatacatgca 540 agtcaattag gtttaaaaat cgaacctcaa aatgctggta aattaactga actagctatg 600 aaacttagag atataataaa tgagaaaata gaaatacaac atccaacttt agctcatata 660 aaaactgtag acttagttga aatatatgat gagccaactc atccagaagc tacttacaaa 720 aatgtagtta tatttggtca aggtcaagtt gacagatctc catgtggaac tggaacaagt 780 gctaaattag ctactttaca tgctaaaggt gaattaaaag taggagaaaa attcgtatat 840 gaaagtatat taggaacttt attcaaaggt gaatatagttg aagaaactaa agttgcagat 900 ttcaatgctg tagtacctaa aataactggt tctgcttata taactggatt taatcatttt 960 gtaatagatg aagaagacccc acttaaacat ggatttattc ttaaataa 1008 <210> 19 <211> 634 <212> PRT <213> Lactobacillus salivarius <220> <221> Peptide <222> (1)..(634) <223> PrdA (LsPrdA) <400> 19 Met Ser Ile Ser Val Glu Gln Ala Lys Glu His Ala Lys Asp Pro Ala 1 5 10 15 Val Leu Cys Cys Arg Arg Glu Ala Gly Lys Val Leu Glu Ala Ala Asp 20 25 30 Phe Glu Asp Pro Thr Leu Phe Asp Asp Tyr Val Ser Ser Gly Leu Leu 35 40 45 Glu Ile Pro Glu Asp Thr Leu Thr Ile Glu Gln Ala Leu Gly Ala Thr 50 55 60 Leu Asn Thr Thr Thr Asp Ala Leu Asn Pro Leu Val Pro Gly Ile Val 65 70 75 80 Asp Asn Ile Gln Gly Asn Glu Glu Ala Ser Glu Ser Asp Lys Asp Glu 85 90 95 Asn Val Glu Glu Glu Thr Pro Val Val Ala Glu Ala Asn Asn Glu Val 100 105 110 Val Asn Ser Thr Ser Ser Asn Gly Thr Phe His Leu Arg Ile Ala Lys 115 120 125 Gly Glu Gly Ile Asp Leu Glu Ile Pro Leu Asp Val Leu Lys Lys Asn 130 135 140 Thr Ala Asn Ser Ala Val Asp Val Pro Lys Ala Glu Thr Ser Ala Asp 145 150 155 160 Val Thr Asn Lys Asp Val Ala Glu Asp Glu Glu Ser Ala Glu Asp Ala 165 170 175 Lys Val Val Arg Thr Leu Thr Lys Lys Tyr Phe Lys Val Asp Glu Val 180 185 190 Lys Phe Gly Asp Thr Thr Lys Phe Asp Gly Thr Thr Leu Tyr Leu Arg 195 200 205 Asn Pro Lys Glu Leu Cys Lys Glu Ala Val Asp Thr Glu Ala Ile Val 210 215 220 Lys Gly Met Glu Ile Glu Ile Ile Thr Pro Asp Asp Tyr Ser Asn Tyr 225 230 235 240 Ser Asn Thr Ile Met Asp Val Gln Pro Ile Ala Thr Lys Glu Gly Asp 245 250 255 Ser Asp Leu Gly Val Gly Val Thr Lys Val Val Asp Gly Ala Val Val 260 265 270 Val Leu Thr Gly Thr Asp Glu Asn Gly Val Gln Val Gly Glu Phe Gly 275 280 285 Ser Ser Glu Gly Pro Leu Asn Glu Asn Ile Met Trp Asn Arg Pro Gly 290 295 300 Ala Val Asp Lys Gly Glu Ile Met Ile Lys Ile Asp Val Val Ile Glu 305 310 315 320 Ala Gly Thr Asn Arg Glu Arg Lys Gly Pro Leu Gly Ala His Leu Ala 325 330 335 Ala Asp Tyr Ile Thr Gln Glu Ile Arg Glu Ala Leu Lys Asp Val Asp 340 345 350 Asp Ser Ser Ala Val Arg Thr Glu Glu Phe Val Gln Lys Arg His Pro 355 360 365 Lys Gln Lys Arg Val Leu Ile Val Lys Glu Ile Met Gly Gln Gly Ala 370 375 380 Met His Asp Asn Leu Ile Met Pro Val Glu Pro Val Gly Thr Leu Gly 385 390 395 400 Ala Lys Pro Asn Val Asp Leu Gly Asn Leu Pro Val Val Leu Ala Pro 405 410 415 Thr Glu Leu Leu Asp Gly Gly Val His Ala Leu Thr Cys Ile Gly Pro 420 425 430 Ala Ser Lys Glu Thr Ser Arg His Tyr Phe Arg Glu Pro Leu Val Glu 435 440 445 Glu Ala Met Ala Asp Glu Asp Ile Asp Leu Val Gly Ile Ala Leu Val 450 455 460 Gly Ser Pro Gln Glu Asn Val Gln Lys Phe Tyr Val Ser Lys Arg Leu 465 470 475 480 Gly Met Met Val Glu Ala Met Asn Leu Asp Gly Ala Ile Val Thr Thr 485 490 495 Glu Gly Phe Gly Asn Asn His Ile Asp Phe Ala Ser His Ile Glu Gln 500 505 510 Ile Gly Glu Arg Gly Val Asp Val Val Gly Met Thr Tyr Ala Ala Val 515 520 525 Gln Gly Gln Leu Val Val Gly Asn Lys Tyr Met Asp Ala Met Val Asp 530 535 540 Asn Asn Lys Ser Arg Gln Gly Ile Glu Asn Glu Ile Leu Glu Asn Asn 545 550 555 560 Thr Leu Ser Arg Glu Asp Ala Ile Arg Ala Leu Ala Met Leu Glu Thr 565 570 575 Lys Met Ala Gly Gly Ser Ile Lys Lys Pro Glu Arg Gln Trp Asn Pro 580 585 590 Asn Val Lys Gln Asn Asn Ile Glu Ile Ile Glu Lys Glu Thr Gly Lys 595 600 605 Lys Ile Asp Leu Val Glu Asn Glu Gln Ser Leu Pro Met Ser Lys Lys 610 615 620 Arg Arg Glu Ile Tyr Glu Lys Asp Ala Gln 625 630 <210> 20 <211> 1905 <212> DNA <213> Lactobacillus salivarius <220> <221> gene <222> (1)..(1905) <223> PrdA (LsPrdA) <400> 20 atgtcaattt cagttgaaca agctaaagaa catgctaagg atccagcagt tctttgctgt 60 agaagagagg caggaaaagt tctggaagct gccgattttg aagacccaac tttgtttgat 120 gactatgtta gttcaggact tttagaaata cctgaagata cgttaactat tgaacaagca 180 ttgggtgcaa cattaaatac tactacggat gcattaaatc ctttagttcc aggtattgta 240 gataatattc agggaaatga agaagcatct gaaagtgata aggacgaaaa tgttgaagaa 300 gaaacaccag ttgtagcaga agctaacaat gaagtagtaa attcaacatc atcaaatggt 360 acattccatt taagaatcgc taaaggtgaa ggtattgatt tagaaatacc tttggatgta 420 ttaaaaaaa accagctaa ctcagctgta gatgtcccca aggcggaac aagtgctgat 480 gtaactata aggatgttgc agagatgaa gatcagcag aagatgctaa agttgttcgt 540 actctaacta aaaatactt caagtagat gaagttaat tggacac aaaaagtttt 600 gatgaacaa cactttactt acgtaatcct aaagaacttt gcaagaagc tgttgatact 660 gaagcaatcg ttaagggtat ggaatcgaa attatcacac ctgatgatta ttccaactat 720 agtacacta ttatggatgt tcaaccaatc gctacaaag aaggagatag tgatttgggt 780 gtaggcgtta caaagttgt ggatggtgct gtagtagtac tcacaggtac tgatgaaaat 840 ggtgtccaag ttggtgaatt tggttctca gaaggtccat tgaatgaaaa tattatgtgg 900 aatcgtcctg gtgcagttga taaaggcgaa atcatgatta agattgt tgttatcgaa 960 gctggaacta accgtgaacg taaaggacct ttaggagcac atttagcagc agactacatt 1020 acacaagaaa ttagagaagc actaaaagat gttgatgata gttcagcagt window 1080 gatttgttc aaaacgtca tcctaagca aagagagtat taattgtaaa agaatcatg 1140 ggtcaggtg caatgcacga taatttaatt atgcctgtgg aaccagttgg tactcttggt 1200 gcaaagccaa atgttgattt aggtaacttg ccagttgtat tagctccaac ggaattatta 1260 gatggtggtg tacatgcttt aacatgtatt ggacctgctt ctaggaaac atccagacat 1320 tacttcagag aacctttggt agagaagca atggctgatg aagatattga tttagttggt 1380 attgcattag tcggttcacc tcaagaaat gttcaaaat tctatgttc taagatta 1440 ggtatgatgg tagagctat gatttagat ggtgctattg ttacacaga aggatttggt 1500 aaaccata tcgacttgc ttctcacatc gaacaattg gtgaaagagg agtagatgtt 1560 gttggaatga catatgctgc tgtccaagga cattagttg ttggtaacaa gtatatggat 1620 gcaatggtgg atacaaca atcccgtcaa ggtattgaa acgaatttct tgaaaacaat 1680 actctatcac gtgagatgc tatcagagct tgcaatgt tggaacaaa gatggctggt 1740 ggatcaatta agaaacctga acgtcaatgg aatccaatg ttaagcaaa taatatcgaa 1800 attattgaaaagaaccgg tagagatt gacttagttg agaatgaaca atctctacca 1860 atgagtaaga agcgtcgtga aatttacgaa aaggatgctc aatag 1905 <210> 21 <211> 240 <212> PRT <213> Lactobacillus salivarius <220> <221> Peptide <222> (1)..(240) <223> PrdB (LsPrdB) <400> 21 Met Ser Leu Lys Lys Tyr Asp Gly Leu Gln Ser Glu Ile Phe Val Pro 1 5 10 15 Ile Thr Pro Thr Pro Val Trp Ala Pro Val Lys Lys Lys Leu Lys Asp 20 25 30 Met Thr Val Ala Ile Val Thr Ala Ala Gly Val His Leu Lys Ser Asp 35 40 45 Lys Pro Phe Asn Leu Ala Gly Asp Thr Ser Tyr Arg Val Val Pro Ser 50 55 60 Thr Ala Thr Asp Asp Glu Leu Met Val Ser His Gly Gly Tyr Asp Asn 65 70 75 80 Thr Asp Val Asn Arg Asp Ile Asn Cys Met Phe Pro Ile Asp Arg Leu 85 90 95 Arg Glu Leu Ala Glu Lys Gly Phe Ile Lys Asn Ile Ala Pro Asn Met 100 105 110 Tyr Thr Cys Met Gly Gly Gly Gly Asp Val Lys Val Phe Thr Glu Glu 115 120 125 Thr Gly Pro Glu Ile Ala Gln Lys Leu Leu Asp Glu His Val Asp Ala 130 135 140 Val Val Met Thr Ala Gly Gly Thr Cys His Arg Thr Ala Val Ile Val 145 150 155 160 Gln Arg Ala Ile Glu Ser Val Gly Ile Pro Thr Ile Ile Ile Ala Ala 165 170 175 Leu Pro Pro Val Val Arg Gln Gln Gly Ser Pro Arg Ala Val Ala Pro 180 185 190 Arg Val Pro Met Gly Ala Asn Ala Gly Glu Pro His Asn Val Glu Met 195 200 205 Gln Thr Gly Ile Leu Lys Asp Thr Leu Glu Gln Leu Glu Lys Leu Asp 210 215 220 Ser Pro Gly Lys Ile Val Pro Leu Pro Tyr Glu Tyr Ile Ala Asn Ile 225 230 235 240 <210> 22 <211> 726 <212> DNA <213> Lactobacillus salivarius <220> <221> gene <222> (1)..(726) <223> PrdB (LsPrdB) <400> 22 atgagtctta agaaatatga tggactacaa tccgaaatat ttgtacctat tactcctacg 60 ccagtgtggg ctccagttaa aaagaagcta aaagatatga ctgtagcaat tgtaactgct 120 gctggtgtac atttgaaatc agataaacca tttaatttag ctggtgatac ttcatataga 180 gtagtacctt caactgcaac tgatgatgaa ttgatggtat cacatggtgg ttatgataac 240 actgatgtta acagagatat taactgtatg ttcccaattg atagattaag agaacttgca 300 gagaaaggat ttattaagaa tattgcgcca aacatgtata catgtatggg tggtggtgga 360 gacgttaaag tctttactga agaaactggt ccagaaattg cccaaaaatt attggatgaa 420 catgtagatg ctgtcgtaat gactgctggt tgaggtacct gtcatagaac tgccgtgatc 480 gtgcagagag ctattgaatc agttggtatc ccaacaatta ttattgcagc cttacctcca 540 gtagtacgtc aacaaggatc tcctagagct gttgctcctc gagttcctat gggggctaat 600 gccggagaac cacacaacgt cgaaatgcaa acaggtattt tgaaagatac gttagagcaa 660 ttagaaaaat tagattcccc aggtaagatt gtgccactac catatgaata tatagcaaat 720 atatag 726 <210> 23 <211> 105 <212> PRT <213> Lactobacillus salivarius <220> <221> Peptide <222> (1)..(105) <223> PrdH (LsPrdH) <400> 23 Met Glu Glu Gln Ser Thr Gly Phe Asp Lys Leu Lys Tyr Ala Ser Thr 1 5 10 15 Glu Arg Val Trp Glu Gly Ile Ile Ile Glu Leu Thr Asp Ala Ser Val 20 25 30 Ile Ile Asp Leu Lys Gly Arg Leu Gly Arg Leu Glu Ile Pro Asn Arg 35 40 45 Met Ile Ile Ser Asp Tyr Glu Leu Lys Val Gly Gln Glu Val Ala Phe 50 55 60 Leu Met Ser Tyr Pro Glu Val Leu Asp Ser Glu Pro Asn Gln Lys Tyr 65 70 75 80 Leu Gly Ala Leu Asn Ala Tyr His Lys Lys Met Lys Glu Ile Lys Glu 85 90 95 Lys Gln Arg Arg Asp Lys Asn Glu Ser 100 105 <210> 24 <211> 318 <212> DNA <213> Lactobacillus salivarius <220> <221> Gene <222> (1)..(318) <223> PrdH(LsPrdH) <400> 24 atggaagaac aaagtacagg atttgacaag ttgaaatatg cctcaactga aagagtatgg 60 gagggtataa taatagaatt gacagatgcg agtgtcataa ttgatcttaa aggacgtcta 120 ggtagactag aaattcctaa tagaatgatt attagtgact atgagttgaa agtcggtcag 180 gaagtagcat tcttaatgtc atatcccgaa gttttggata gtgaacctaa tcaaaaatat 240 ttaggagcac taaatgcata ccataaaaaa atgaaagaaa taaaagaaaa gcaaaggaga 300 gataaaaatg agtcttaa 318 <210> 25 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> PrdA(C421A)-F <400> 25 ggtatccatg cattaactgc cataggacct gcatcaaaag 40 <210> 26 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> PrdA(C421A)-R <400> 26 cttttgatgc aggtcctatg gcagttaatg catggatacc 40

Claims

1. A microorganism expressing active D-proline reductase, wherein the activities of PrdA protein, PrdB protein and PrdH protein are enhanced, wherein the microorganism is a microorganism of the genus Escherichia, The PrdH protein is a protein encoded by a gene ORF existing between the gene encoding the PrdA protein and the gene encoding the PrdB protein, wherein the activity of the PrdA protein consisting of the amino acid sequence of SEQ ID NO: 3, the PrdB protein consisting of the amino acid sequence of SEQ ID NO: 5, and the PrdH protein consisting of the amino acid sequence of SEQ ID NO: 1 is enhanced; or The activities of the PrdA protein consisting of the amino acid sequence of SEQ ID NO: 19, the PrdB protein consisting of the amino acid sequence of SEQ ID NO: 21, and the PrdH protein consisting of the amino acid sequence of SEQ ID NO: 23 are enhanced.

2. The microorganism expressing active D-proline reductase according to claim 1, wherein the activity of one or more proteins selected from the group consisting of PrdD, PrdE and PrdE2 is additionally enhanced.

3. The microorganism expressing active D-proline reductase according to claim 1, wherein the activity of one or more proteins selected from the group consisting of PrdC, PrdG and PrdF is additionally enhanced. The microorganism expressing active D-proline reductase according to claim 1 , wherein the microorganism is Escherichia coli.

5. A method for producing active D-proline reductase, the method comprising the following steps: Cultivating the microorganism according to any one of claims 1 to 4 in a culture medium, and The active D-proline reductase is recovered from the microorganism or the culture medium. 6 . A method for producing one or more selected from 5-aminovaleric acid, γ-aminobutyric acid and 5-amino-4-hydroxyvaleric acid using the microorganism according to any one of claims 1 to 4 .

7. Use of PrdH protein for preparing active D-proline reductase by converting inactive D-proline reductase into active D-proline reductase and co-expressing it with PrdA protein and PrdB protein, wherein the PrdH protein is a protein encoded by a gene ORF present between a gene encoding the PrdA protein and a gene encoding the PrdB protein, wherein when the PrdH protein consists of the amino acid sequence of SEQ ID NO: 1, the PrdA protein consists of the amino acid sequence of SEQ ID NO: 3 and the PrdB protein consists of the amino acid sequence of SEQ ID NO: 5; and When the PrdH protein consists of the amino acid sequence of SEQ ID NO:23, the PrdA protein consists of the amino acid sequence of SEQ ID NO:19 and the PrdB protein consists of the amino acid sequence of SEQ ID NO:

21.

8. A method for producing a microorganism expressing active D-proline reductase, the method comprising the following i) or ii): i) transforming a host cell with an expression cassette comprising the prdA gene, and transforming the host cell with an expression cassette comprising prdB and prdH genes; ii) transforming a host cell with an expression cassette comprising the prdA and prdH genes, and transforming the host cell with an expression cassette comprising the prdB gene, wherein the microorganism is a microorganism of the genus Escherichia, The PrdH protein is a protein encoded by a gene ORF existing between the gene encoding the PrdA protein and the gene encoding the PrdB protein, wherein the activities of the PrdA protein consisting of the amino acid sequence of SEQ ID NO: 3, the PrdB protein consisting of the amino acid sequence of SEQ ID NO: 5, and the PrdH protein consisting of the amino acid sequence of SEQ ID NO: 1 are enhanced in the microorganism; or The activities of the PrdA protein consisting of the amino acid sequence of SEQ ID NO: 19, the PrdB protein consisting of the amino acid sequence of SEQ ID NO: 21, and the PrdH protein consisting of the amino acid sequence of SEQ ID NO: 23 are enhanced in the microorganism.

9. The method for producing a microorganism expressing active D-proline reductase according to claim 8, wherein the activity of one or more proteins selected from the group consisting of PrdD, PrdE and PrdE2 is additionally enhanced.

10. The method for producing a microorganism expressing active D-proline reductase according to claim 8, wherein the activity of one or more proteins selected from the group consisting of PrdC, PrdG and PrdF is additionally enhanced.

11. The method for producing a microorganism expressing active D-proline reductase according to claim 8, wherein the microorganism is Escherichia coli.

Citation Information

Patent Citations

  • Photosensitive resin composition, photosensitive resin layer and color filter using the same

    KR1020170088632A

  • KR2015-0029526